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Background: Coronary artery bypass grafting (CABG) surgery and percutaneous 
coronary intervention (PCI) procedures have been associated with substantial financial costs 
in Texas. The annual hospital charges in 2016 for CABG surgeries and PCI procedures in 
Texas were $3.6 billion and $4.1 billion, respectively. Recently, these two procedures have 
become a target for bundled payment initiatives. Due to the lack of information about the 
demographics and variations associated with CABG and PCI episode payments for 
commercially insured patients, more research needs to be conducted to understand the 
magnitude of payments and the drivers of variation in payments in Texas. Objective: This 
study aimed to fill the gap by examining CABG and PCI medical costs through episode 
payment models. The first objective was to estimate both CABG and PCI episode payment 
variations in patient demographics for a large sample of the commercially insured population 
in Texas. The second objective was to examine the payment components that drive 
variability in 90-day episode payments across Texas. Methods: The study design was a 
retrospective cohort study of commercially insured patients 18 years of age and older 
undergoing CABG surgeries and PCI procedures in Texas regions for the years 2014 to 2018. 
Using Optum Clinformatics® DataMart (CDM): administrative claims data. For this study, 
the average 90-day episode payment for patients undergoing CABG surgeries and PCI 
procedures were first calculated and then assessed if there were wide demographic variations 
in the payments. The total 90-day payment was derived as the sum of the procedure and 
hospitalization payment and the payment associated with post-discharge utilization. All 
dollars were adjusted to 2018 values. Multiple linear regression models were used to identify 
factors impacting the 90-day total episode payments. After that, the variation in payments 
and the primary drivers of payment variations were identified. Hospitals and regions were 
divided into quartiles based on the mean episode payment for CABG surgeries and PCI 
procedures. Total episode payments were subdivided into five payment components (index 
procedure, professional services, post-acute care, readmission, and pharmacy) to investigate 
which components drove variability significantly by comparing them across high- and low-
cost quartiles. Results: A total of 999 CABG episodes and a total of 2691 PCI episodes were 
identified. The mean (SD) 90-day episode payments at patient level for CABG surgeries and 
PCI procedures were $81,330 ($47,382) and $53,842 ($44,603), respectively. Certain patient 
factors, including age, patient region, comorbidities, type of insurance, length of stay, and 
readmission stage had effects on 90-day episode payments. The average 90-day payment at 
the hospital level in the highest- and in the lowest-payment quartiles ranged from $106,148 
to $61,028, representing a difference of $45,121 (74%) for CABG surgeries. They ranged 
from $74,510 to $33,696, representing a difference of $40,814 (121%) for PCI procedures. 
The index procedure was the primary driver of 90-day CABG episode payment variation of 
49%, while both the index procedure and the post-acute care were relatively similar sources 
of 90-day PCI episode payment variation of 37% and 36%, respectively. Conclusions: 
Payment variations existed widely in 90-day episode payments for commercially insured 
patients undergoing CABG surgeries and PCI procedures across Texas. Focusing on reducing 
readmissions and targeting the index payment component, which has contributed to a large 
proportion of episode payment variations, might be a potentially effective approach when 
developing initiatives to reduce CABG- and PCI-related costs and improve efficiency.  
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Coronary revascularization procedures (CRPs), such as coronary artery bypass 
grafting (CABG) surgery and percutaneous coronary intervention (PCI), are common 
invasive procedures for patients with coronary artery disease (CAD). According to the 
National Center for Chronic Disease Prevention and Health Promotion, Division for Heart 
Disease and Stroke Prevention (DHDSP), CAD is a term for “a plaque buildup in the wall of 
the [coronary] arteries that supply blood to the heart [which] causes the inside of the arteries 
to narrow over time.”[1] As a result, the growing plaque limits the blood to the heart, which 
results in a reduced supply of oxygen to the heart. Consequently, patients with CAD have a 
high risk of angina, which is chest pain or discomfort, as well as a myocardial infarction 
(MI), which is commonly known as a heart attack.[2] Patients with significant plaque buildup 
will often undergo a CABG surgery or a PCI procedure.  
CABG is an invasive procedure that uses the patient’s own veins to bypass narrowed 
coronary arteries to restore the blood flow to the heart.[3] Not only does the surgery reduce 
and relieve chest pain, but it may also prolong life for patients with severe CAD. 
Alternatively, PCI is a minimally invasive nonsurgical procedure that opens up the blocked 
coronary arteries to improve blood flow in one or more parts of the coronary circulation.[4] 
Coronary revascularization with PCI primarily involves the use of balloon angioplasty and 
intracoronary stenting.[4] Both CABG surgeries and PCI procedures have been common 
clinical interventions for patients with CAD. 
There are numerous risk factors that contribute to CAD. These risk factors include 
poor diet, physical inactivity, and smoking. In addition, people who have high blood 
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pressure, high cholesterol, diabetes, or a family history of the condition are more likely to 
develop CAD.[5, 6] Approximately half of American adults have one of the following risk 
factors: smoking, high blood pressure, and/or high cholesterol.[7]The risk for CAD increases 
for men starting at age forty-five, while the risk for women increases starting at age fifty-
five.[5, 8] The health prognosis of men with CAD after treatment is better than that of 
women’s for short-term revascularization.[9-12] Females have higher mortality, and they are 
more likely to suffer major adverse cardiovascular events than males after undergoing CABG 
or PCI procedures.[9, 10] 
The prevention and intervention levels of care for CAD can be classified as primary, 
secondary, and tertiary.[13] The primary level includes taking action to control risk factors 
with medications and making healthy lifestyle changes such as exercising, ceasing smoking, 
and controlling high blood cholesterol and high blood pressure. The secondary level includes 
undergoing non-invasive CAD screening diagnostics (e.g., positive emission tomography, 
electrocardiogram, CT, and general imaging) as well as taking medications (e.g., antiplatelet 
therapy and beta-blockers). The tertiary level includes undergoing invasive diagnostic 
procedures (e.g., angiography) and coronary revascularization procedures (e.g., CABG 
surgeries and PCI procedures).  
In 2018, the American Heart Association (AHA) reported that the annual medical 
costs associated with CAD ($9 billion) make it one of the ten most expensive health 
conditions treated in U.S. hospitals.[8] In addition, medical costs related to CAD were 
projected to increase by about 100 percent between 2013 and 2030.[8] Medical spending on 
CRPs (i.e., CABG surgeries and PCI procedures) in the United States is extremely high 
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compared to other-similar high income-countries, including Canada, the United Kingdom, 
and Switzerland. For example, a previous study found that CABG in the United States is 
approximately twice as expensive compared to Canada.[14] Furthermore, in 2014, the average 
cost (in employer-sponsored plans) for a CABG surgery in the United States was $78,318, 
whereas the average cost (average private sectors) was $24,059 in the United Kingdom and 
$34,224 in Switzerland.[15, 16] Moreover, the average cost (in employer-sponsored plans) for a 
PCI procedure in the United States was $31,620, whereas the average costs (average private 
sectors) for a PCI procedure in the United Kingdom and Switzerland were $7,264 and 
$10,066, respectively.[16] In light of the reported high costs of CABG and PCI nationwide, it 
is necessary to begin investigating these costs statewide as well.  
CAD and the Costs of CABG and PCI in Texas  
In 2014, the leading cause of death in Texas was CAD, resulting in 175.8 deaths per 
100,000 people.[17] In 2016, 1.64 million adults over 18 (6.1% of the population) were 
diagnosed with CAD.[17, 18] Not only is CAD Texas’ biggest killer,[19] but it is also one of the 
costliest health conditions.[20] The costs of CABG and PCI procedures in Texas have 
previously been assessed only to a very limited extent. To our knowledge, costs were not 
measured by private insurance payments (i.e., from a payer perspective) but by billing 
charges despite the fact that in 2016, more than forty-eight percent of Texas’ population was 
covered by private insurance.[21] Moreover, private insurance in Texas has not been effective 
at controlling hospital inpatient care payment and, consequently, it was the key driver of 
regional variation in healthcare spending in Texas.[22] In fact, Texas had the third highest 
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annual average spending growth rate (6.9%) in private health insurance between the years 
2001–2014 among all the states.[23]  
Differentiating among the terms cost, charge, and reimbursement is a vital step for 
understanding healthcare cost studies. The term cost could be considered and evaluated from 
different perspectives. To patients, cost is the amount payable out-of-pocket for healthcare 
services. [24] To providers, cost becomes the expense incurred to deliver healthcare services 
to a patient.[24] To payers, cost includes the amount payable to the provider for rendered 
healthcare services to a patient.[24] 
Billing charges have been described as the amounts that healthcare providers asked 
for the provided services. However, commercial payors generally offer plans that contract 
with healthcare providers for rates discounted from charges, causing the charges to be an 
inaccurate reflection of actual payments to providers. Reimbursement is the amount that a 
third-party payer negotiates as payment to healthcare providers (typically less than the 
amount of the billing charge).[24, 25] The reimbursement amount may be in different forms 
such as fee-for-service, per diem, capitation, or episode of care (e.g., diagnosis-related group 
[DRG]).[25] For the purpose of this research, episode payments referred to reimbursements. 
They have been described as the allowed amounts, including insurance company net pay and 
insured member out-of-pocket payments (e.g., co-pay, coinsurance, and deductible), to 
healthcare providers for the giving medical services.  
The Center for Health Statistics in Texas and other state agencies have provided 
insight to costs using billing charges as units of cost. For example, hospital charges for CAD 
in Texas exceeded $6 billion in 2010 and rose to $8 billion in 2016.[26, 27] According to the 
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Texas Department of State Health Services (DSHS), the average hospital charge for PCI per 
case was $126,832 in 2016, while the average hospital charge for CABG surgery per case 
was $234,560.[26]  
Furthermore, there were considerable variations in the mean charges of CABG and 
PCI that had been performed across Texas.[28] For example, in 2016 the approximate mean 
charge per case of CABG surgeries performed in El Paso, Houston, McAllen, and Austin in 
thousands of dollars were $386, $257, $287, and $236, respectively.[26] The approximate 
mean charge per case of PCIs performed in 2016 in El Paso, Houston, McAllen, and Austin 
in thousands of dollars were $182, $124, $137, and $141, respectively.[26] These variations in 
the charges for CABG and PCI performed in these different areas suggested the need for 
further analysis in cost. Patient demographic factors, including patient regions, could have 
contributed to the variation in payments. As a result, this study examined medical costs and 
variability associated with CABG and PCI treatments throughout Texas. 
Hospital Referral Regions 
Similar to other states, Texas has a number of hospital referral regions (HRRs) 
determined by the Dartmouth Atlas of Health Care (DAHC). These regions reflect 
geographic units of analysis to define regional health care markets. They have been defined 
by documenting where patients were referred for neurosurgery and for major cardiovascular 
surgical procedures.[29] HRRs are comprised of hospital service areas by zip codes grouped 
together based on the referral patterns for tertiary and complex medical care.[29] Hospital 
service areas were assigned to HRRs where the greatest proportion of major cardiovascular 
procedures were performed.[29] 
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Texas has twenty-two different regions, and some of these regions overlap other state 
boundaries.[29] In addition, some neighboring state regions overlap Texas boundaries. For 
example, there are some New Mexico areas (i.e., Alamogordo, Las Cruces, Deming, Truth or 
Consequences) that belong to the Texas El Paso HRR, while there are also some Texas areas 
(i.e., Texarkana, Atlanta, Marshall, Carthage) that belong to neighboring state HRRs, 
including the Arkansas Texarkana HRR and Louisiana Shreveport HRR. Because each HRR 
has at least one city with a hospital where major surgical procedures are performed, 
researchers have widely used HRRs as the geographic unit of analysis in their research.[22, 30-
32]  
Episode (Bundled) Payment Models 
In an effort to focus on value-based medicine and quality of care in healthcare 
spending rather than on volume (i.e., quantity), researchers and policymakers have proposed 
clinical episode (bundled) payment models for certain diagnoses and procedures, including 
episodes designed around CABG surgeries and PCI procedures.[33-36] The episode payment 
typically is a predetermined bundled payment for all the care that a patient receives for a 
procedure or treatment of a particular disease or condition during a defined period of time. 
An episode may include inpatient stay, professional services, readmission, post-acute care, 
and other related services to the inpatient stay and services received within 90-days of the 
initial hospital discharge. In episode payment model, healthcare providers participate in this 
model through an agreement with payers and receive a set negotiated amount for the multiple 
services patients received during an episode of care. Therefore, reimbursement is linked to 
the healthcare performance within the episode of care. Healthcare providers are held 
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accountable for the total costs of care and could be subject to financial consequences for low-
quality care. Under an episode payment model, healthcare providers through the risk sharing 
strategy are incentivized to reduce unnecessary services and improve health care 
coordination across healthcare settings. 
The Centers for Medicare and Medicaid Services (CMS) is experimenting with 
bundled payment approaches, which are also known as episode payment models (EPMs), 
with the aim of improving quality of care and reducing costs by aligning incentives among 
healthcare providers. In 2013, CMS introduced four voluntary bundled payment 
models aiming to increase quality and care coordination at a lower cost.[35, 37] These four 
models were included under the Bundled Payment for Care Improvement (BPCI) initiatives. 
More bundled models were sequentially introduced, including the first CMS mandatory 
model, which was the Comprehensive Care for Joint Replacement (CJR) of 2016. 
Furthermore, in 2018, CMS announced a new voluntary episode model for 29 inpatient 
clinical episodes and 3 outpatient clinical episodes.[34] This included 90-day time periods for 
CABG and PCI episodes to have insight into the events occurring to patients after discharge.  
Furthermore, the Quality Payment Program, which was established by the Medicare 
Access and CHIP Reauthorization Act of 2015 (MACRA), considered CABG and PCI 
episodes as Advanced Alternative Payment Models (Advanced APMs) used to modify 
healthcare providers’ payments.[38, 39] One of the goals of these models is to reduce costs by 
reducing the amounts of variations in high-cost surgical procedures, including CABG 
surgeries and PCI procedures. With the recent heightened focus on payment reform and 
increased interest in applying EPMs for Medicare populations, these models are also likely to 
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be embraced by private payers.[36, 40, 41] For example, private employers and the Medicaid 
program of Arkansas have already started episode payment initiatives for CABG surgeries 
and PCI procedures.[42]  
Previous research has shown a wide variation in Medicare post-acute care payments 
between hospitals that participated in bundled payments and those that did not.[43-45] Such 
studies found that episode payments for surgical procedures, including lower extremity joint 
replacement, might have the potential to decrease healthcare payments while maintaining or 
improving quality of care.[44-47] Furthermore, other studies found that bundled payments for 
joint replacement and for shoulder arthroplasty procedures led to a significant decrease in 
costs as well as a significant decrease in readmission rates.[48, 49] Studies that examined 
clinical episodes related to cardiac surgeries (i.e., cardiac valve replacement, CABG) found 
that bundled payment initiatives were not associated with the index procedure costs but that 
they were associated with lowering post-acute care spending.[44, 46]  
As CABG and PCI are common but expensive for patients with heart disease,[8] these 
procedures might be the first heart disease treatments targeted for mandatory episode 
payments. Payers, cardiology specialists, policy makers, and other parties have been making 
efforts to ensure that cost-effective care and high-value care are delivered consistently for all 
CAD patients.  
The present study focused on understanding the drivers of episode payment variation 
in CABG surgeries and PCI procedures for privately insured populations in Texas. This study 
aimed to provide an understanding of medical care payments in Texas among commercially 
insured patients undergoing CABG surgeries and PCI procedures. This study could provide 
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healthcare payers and providers baseline data for the implementation of sound policies for 
cost reduction and quality improvement in CAD treatment. To this end, patient factors that 
have an impact on episode payment for commercially insured patients having CABG and 
PCI in Texas were discussed. This study also assessed the episode payment components 
(index procedure payment, professional services payment, post-acute care payment, 
readmission payment, pharmacy payment) that drove payment variation. 
Literature Review 
Variations in healthcare costs could be analyzed by using different methodologies to 
estimate costs. Healthcare costs were tracked using different bases, including but not limited 
to cost per episode-of-care basis, cost of overall medical care basis, cost within a treatment 
level basis, cost within a geographic level basis, and cost within a hospital level basis.[22, 50-54] 
Healthcare costs could also be tracked on a spending per beneficiary basis and total per 
capita cost basis.[22, 50, 53, 54] Many cost analysis studies also focused on clinical episodes, 
including surgical procedures such as hip replacement, knee replacement, back surgery, 
colectomy, bariatric surgery, prostatectomy, nephrectomy, carotid endarterectomy, and 
lumbar spinal surgery.[55-63] More importantly, several studies have focused on the drivers of 
payment variation,[31, 51, 55, 56, 58-64] including PCI cost variations,[52, 64] and CABG cost 
variation.[31, 51, 55, 59, 61]  
In particular, the PCI procedure cost variation has been explored in at least two 
studies. Hsia et al. (2014) found that average cost, which was measured based on hospital 
billed charges, varied widely among hospitals for patients undergoing PCI in 
California.[52] Also, Sukul et al. (2019) examined PCI episode payment variation and its 
10 
drivers from 2012 to 2016, considering insurance payment amounts instead of 
charges.[64] After comparing the high- and low-payment hospitals in Michigan, Sukul et al. 
concluded that a wide variation existed in 90-day episode payments and that readmission 
payment was the component with the highest contribution (46.2%) to variation in PCI 
episode payments.[64] These two studies were conducted in two different states (California 
and Michigan) and indicated that variation in costs for PCI procedures existed statewide.  
Similarly, a recent study by Guduguntla et al. (2018) examined CABG episode 
payment variation and its components in seventy-six hospitals in Michigan, and these 
researchers found that a wide variation existed in 90-day episode payments.[51] The study 
found that patients with multiple readmissions as well as components such as index 
procedure, evaluation and management services, and inpatient rehabilitation contributed the 
most to variation in episode payments.[51] Furthermore, the findings of the study indicated 
that among all payment components, readmission had the highest difference rate between the 
highest payment hospitals compared with the lowest payment hospitals.  
In a recent study in 2019, Shubeck et al. investigated CABG episode payment 
variation of Medicare nationwide beneficiaries at the hospital level.[61] These researchers 
found that payment variation between the high- and low-payment hospitals was because of a 
threefold difference in index procedure payment.[61] The findings of the study demonstrated 
that patients with comorbidities incur higher costs than healthier patients. Furthermore, other 
research studies on CABG episode payments for Medicare beneficiaries found that 
significant payment variation existed for CABG episodes.[55, 59] These studies also found that 
the index procedure component was the key driver of payment variations.[55, 59] Because these 
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CABG cost analyses studies focused on Medicare populations, their findings might not be 
generalizable for younger populations or for those with private insurance.[55, 59, 61] 
A study by Wynn-Jones et al. (2019) examined 90-day period CABG payment 
variation targeting the TRICARE adult population and found that significant regional-level 
variation in payment for CABG episodes.[31] This study demonstrated that the payment 
patterns in the TRICARE data were different from those observed in the Medicare data. The 
index procedure payment, which was described as the estimate amount for CABG 
hospitalization, was the main driver of payment variations. Moreover, the readmission 
payment had the highest difference rate between the highest payment regions compared with 
the lowest payment regions. Table 1 summarizes a variety of previous cost variation studies 
on CABG and PCI episodes. 
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Main Measure Amount 
Component with the 
Highest 
Contribution (%) to 
Variation in Costs  
Study Characteristics 
Hsia et al. (2014)[52] PCI Median hospital charges $88,350 N/A • Variation in index procedure charges at hospital level 
• Commercially insured patients in California 
• Study period: 2011 
Sukul et al. (2019)[64] PCI Mean Medicare 
reimbursement 
$24,696 Readmission  
(46.2%) 
• Variation in 90- day episode payment at hospital level 
• Medicare and BCBS patients in Michigan  
• Study period: 2012 to 2016 
Birkmeyer et al. (2010)[55] CABG Mean Medicare 
reimbursement 
$36,049 Index procedure 
(53.8%) 
• Variation in 30- day episode payment at hospital level 
• Medicare beneficiaries nationwide 
• Study period: 2005 








• Variation in 30- day episode payment at hospital level 
• Medicare beneficiaries nationwide 
• Study period: 2005 to 2007 
Guduguntla et al. (2018)[51]  CABG Mean Medicare 
reimbursement 
$48 571 Index procedure 
(49%)* 
• Variation in 90- day episode payment at hospital level 
• Medicare (>75%) and BCBS patients in Michigan  
• Study period: 2012 to 2015 






• Variation in 30- day episode payment at hospital level 
• Medicare beneficiaries nationwide 
• Study period: 2010 to 2013 
Wynn-Jones et al. (2019)[31]  CABG Mean TRICARE payment $44,983 Index procedure 
(57%) 
• Variation in 90-day episode payment at HRR level 
• TRICARE beneficiaries nationwide aged 18-65  
• Study period: 2011 to 2014 
*Rate was calculated manually from the article results using the equation of contribution of payment variation (see Equation 2)  
**The highest decile mean payments 
***The lowest decile mean payments 
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Substantial gaps remain in our knowledge of the determinants of the economic burden 
of invasive heart procedures in Texas. There is a lack of studies about medical care costs for 
commercially insured patients undergoing CABG and PCI procedures in Texas. In addition, 
moving from the existing volume payment model (fee-for service) to a model that focuses on 
value and bundled payments of healthcare spending poses daunting challenges. 
In the case of Texas, it was indicated that unexplained variability in healthcare costs 
have been observed. In the article “The Cost Conundrum,” Gawande (2009) explored the 
significant Medicare cost variation between McAllen and El Paso, two areas with similar 
disease burden and patient demographics.[65] The findings indicated that McAllen had almost 
twice the Medicare spending per person in 2006 compared to El Paso. It was unclear why 
such variation in costs occurred between two comparable areas within the same state. In 
response to this article, research was conducted on the medical costs of the two regions using 
a commercially insured population.[30] This follow-up study was found that total spending per 
member per year in McAllen was seven percent lower than in El Paso for a privately insured 
population.[30] Because this study considered only two regions in Texas, further research on 
Texas geographic variation in healthcare costs was recommended. 
It was expected that even for well-defined procedures, such as a CABG and PCI 
procedures, there would be an observation of unexplained variability in episode payments. In 
this present study, episode payments were estimated for both CABG and PCI procedures for 
patients in multiple Texas regions. More specifically, this study estimated the payment 
components (i.e., index procedure payment, professional services payment, post-acute care 
payment, readmission payment, pharmacy payment) as well as mean payments in Texas. 
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This study then explained the proportion of the observed variation after accounting for 
patient factors. The results of this study may interest policymakers, healthcare payers, and 
healthcare providers for designing policies and initiating clinical quality improvements. The 
findings of this study could be used for future cost-effectiveness analysis of interventions for 
CAD. 
Statement of Problem 
The cost of treatments for cardiovascular diseases, including CAD, continues to 
increase for public and private payers.[8] The literature showed public payers have done a 
better job in controlling prices than private payers in Texas.[22] Prices paid to hospitals in 
Texas by private payers were 244% higher relative to public payers.[66] Variability in 
healthcare spending is hurting efficiency and causing spending waste. It has been found that 
both price and utilization drove variation in spending across Texas.[22] Despite the effect and 
magnitude of CAD and associated invasive treatments in Texas, there has been limited 
examination of cost variation and cost drivers associated with CAD treatments, especially the 
costly but common invasive procedures of CABG and PCI. In order to support policymakers, 
payers, and hospitals, it is important that rigorous quantitative studies be conducted to 
understand CABG and PCI episode payments for commercially insured patients in Texas.  
Examining payment components and geographic variation associated with average 
payments for commercially insured patients undergoing CABG or PCI across Texas would 
help establish policies to improve efficiency and decrease wasteful spending in healthcare in 
Texas. The purpose of this research was to describe CABG and PCI episode payment 
components and to examine payment variation using a Texas representative commercially 
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insured cohort. Medical providers, health insurers, and policymakers who better understand 
influencing factors and cost drivers may design initiatives to reduce healthcare spending 
through value-based payments and may develop strategies for bundled payments for CABG 
surgeries and PCI procedures.  
Public Health Significance 
An objective assessment of the economic burden of an invasive heart intervention 
leads to a better allocation of public health and healthcare resources. Estimating the payment 
for an invasive clinical intervention requires a better understanding of the relevant incurred 
costs. Such studies inform employers, insurers, and providers what cost elements have 
significant impacts on total episode payments.  
The prevalence of morbidity and mortality associated with heart disease is noticeable 
in Texas.[17, 18] Moreover, the considerable expenditures and volume of CABG surgeries and 
PCI procedures reflect the importance of conducting a relevant cost analysis study using 
clinical episode models. A cost analysis study of CABG and PCI episode payments for the 
Texas population 18 years of age and older is crucial, given that patients aged 45 and 55 for 
males and females, respectively, are at-risk for CAD. Furthermore, one study found that 30% 
of the patients hospitalized for heart attacks from 1995 to 2014 were between the ages of 35 
and 54, and there was a 5-percentage point increase in the number of younger heart attack 
victims over that period.[67] In addition, the target population of this study, patients 18 years 
of age and older, represented a high proportion of the Texas labor force; therefore, an adverse 
financial effect on this population would have significant economic impact on employer 
sponsored health plans.  
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Study Goals 
 The goals of this study were the following: 1) to examine variation in CABG and 
PCI episode payments across Texas and 2) to examine the payment components that drive 
the variability.  
Specific Aims 
Aim 1A: To evaluate the variation in 90-day CABG episode payments in the Texas 
HRRs among commercially insured patients 18 years of age and older undergoing CABG 
surgeries by using Optum claims data from 2014-2018, controlling for patient age, gender, 
and comorbidities. 
• H0: 90-day CABG episode payments are equal among the Texas HRRs for commercially 
insured patients. 
• Ha: At least one HRR in Texas has a significantly different 90-day CABG episode 
payment from the other regions for commercially insured patients. 
Aim 1B: To evaluate the variation of the 90-day PCI episode payments in Texas 
HRRs among commercially insured patients 18 years of age and older undergoing PCI 
procedures by using Optum claims data from 2014-2018, controlling for patient age, gender, 
and comorbidities. 
• H0: 90-day PCI episode payments are equal among the Texas HRRs for commercially 
insured patients. 
• Ha: At least one HRR in Texas has a significantly different 90-day PCI episode payment 
from the other regions for commercially insured patients. 
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Aim 2A: To examine how the payment components (index procedure, post-acute 
care, professional services, readmission, pharmacy) drive variability in the 90-day CABG 
episode costs in Texas among commercially insured patients 18 years of age and older for 
Optum claims data from 2014-2018. 
Aim 2B: To examine how the payment components (index procedure, post-acute 
care, professional services, readmission, pharmacy) drive variability in the 90-day PCI 
episode costs in Texas among commercially insured patients 18 years of age and older using 
Optum claims data from 2014-2018. 
Conceptual Framework 
For this study, using the Donabedian conceptual framework to measure costs of 
CABG and PCI episode payments provided an understanding of the primary outcome 
payment for the two defined procedures across different facilities and providers. The 
framework was useful for recognizing the different measures in terms of the classical 
structure-process-outcome Donabedian triad. For the structure measures, the study included 
patient demographics (age, gender, region, comorbidities). For the outcome measures, there 
were the two primary outcomes (i.e., 90-day CABG episode payment, 90-day PCI episode 
payment) as well as five secondary outcomes (index procedure payment, professional service 
payment, post-acute care payment, readmission payment, and pharmacy payment). The 
Donabedian framework was an appropriate approach for aggregating claims data into 
episodes to assess specific invasive procedure associated payments. As a result, the proposed 
conceptual model was developed (see Figure 1) for this study to estimate factors and to 
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identify cost drivers contributing to the 90-day episode payments of CABG and PCI 
procedures across Texas.  
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A. 90-Day CABG Episode Payment ($) 
 




Structure Process Outcome 
Payment Components 
• Index Procedure Payment ($)  
• Professional Services Payment ($) 
• Post-acute Care Payment ($) 
• Readmission Payment ($) 
• Pharmacy Payment ($) 
Patient Factors 
• Age  
• Gender  
• Region 




Aim 2A Aim 2B 
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METHODS 
The present research focused on commercially insured patients 18 years of age and 
older who were covered by private insurance and who underwent CABG surgery or a PCI 
procedure for the years 2014-2018. This study used Optum administrative claims data of a 
commercially insured population to identify payments and to quantify episode payment 
variation related to these CABG surgeries and PCI procedures across Texas. Payments were 
represented by commercial insurance payers in terms of the total cost amounts for the index 
procedure and the 90-day care after procedure for patients who underwent CABG surgery or 
PCI procedure. The episode payment included payments related to index procedure, 
professional services, post-acute care, readmissions, and prescription drugs. For inpatient 
clinical episodes, this study computed cost information for medical care from the date of 
hospital admission to 90-days post-discharge. For outpatient clinical episodes, it computed 
payment information from the index procedure date to 90-days post-discharge. Although this 
study was based entirely on commercially insured patients undergoing CABG surgeries and 
PCI procedures from 2014-2018, it excluded information for patients discharged toward the 
end of 2018 (if the 90-day post-procedure requirement occurred in 2019). 
Study Design 
This research was a retrospective cohort study using secondary datasets. All patient 
records were de-identified. Records of the appropriate Texas population were selected form 
the database, which included those patients that underwent coronary revisualization 
procedures, CABG surgeries or PCI procedures, from January 1, 2014, to October 2, 2018. 
All patients in the present study were included because they were identified to have had 
21 
CABG surgeries or PCI procedures at some point during the study timeframe. Although the 
study period was from 2014 to 2018, claims data from 2013 were obtained and used to track 
patient comorbidities. Each of the patients was followed through the defined study period to 
estimate total episode payments. The episode period referred to index procedure plus a 90-
day post-procedure follow up period. The 90-day period was used because it is the same 
length of time employed by CMS in its EPM design for CABG surgeries and PCI 
procedures.[34] The term 90-day episode payment was used in this research, and this term 
seemed reflected a payment for a total window of 90-day period for each episode of care. 
However, this period in reality is more than 90-days depending on the hospitalization period, 
which could have added a few days. Geographic regions in Texas were defined by 
aggregating data at the patient zip code level to the HRR level (see Figure 2). All analyses 
were performed from a payer perspective.  
Sampling Frame and Study Population 
The sampling frame of the study included all insured members of Texas HRRs 
through a single private payer from 2014 to 2018. For conditions where CABG surgeries and 
PCI procedures have occurred, insured patients were in at least 270 days of continuous 
enrollment. All patients in this study had been enrolled for at least 180 days prior to the 
CABG surgery or PCI procedure and at least 90 days post-discharge. As a result, claims data 
from 2013 were obtained to track prior comorbidities for patients who underwent CABG 
surgeries or PCI procedures during the first half of 2014. All members were enrolled in fee-
for-service plans (i.e., preferred provider organizations [PPO] and point of service plans 
[POS]). For the study, the procedures of interest (CABG and PCI) were detected according to 
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specific inclusion and exclusion criteria. Complete enrollment observations were included 
with health plans of fee-for-service payment, including PPO and POS plans. Patients who 
underwent CABG surgeries or PCI procedures were identified according to the diagnosis and 
procedure codes (see Appendices A & B). All observations in the study were limited to 
patients who were 18 years of age and older as of the index procedure admission date. 
Insured members within HRRs that belong to other states were excluded. Patients that had 
claims with inappropriate or missing data (missing zip codes, inappropriate or missing 
admission dates or discharge dates of index procedures) were also excluded. Readmission 
payments were included for readmitted patients within 90-days after discharge the date of the 
index procedure. Patients who died during the episode window could not be identified; 
instead; patients, with zero claims during the 90-days post-discharge were excluded. 
Texas is the second largest state, and it has the second largest population in the 
United States, which is why it is ideal for obtaining information for a large number of CRPs. 
For example, in Texas, the number of reported CABG surgeries and PCI procedures in 2016 
were 15,876 and 33,750, respectively.[26] As a result, a significant number of cases were 
expected by using Optum claims database, which covers a considerable number of the 
commercially insured patients in Texas.[68] For the claims data extraction, this study used the 
diagnosis and procedure codes established by the Healthcare Effectiveness Data and 
Information Set (HEDIS) and obtained from the Center for Healthcare Data at The 
University of Texas Health Science Center at Houston School of Public Health as well as the 
trigger codes by the CMS.[69]  
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Both Current Procedural Terminology (CPT) codes and Medicare Severity Diagnosis 
Related Group (MS-DRG) codes were used to identify PCI procedures because both inpatient 
and outpatient settings perform PCI. This was an important aspect of PCI insurance payment. 
Among PCI episodes, episodes were included when the CPT codes (i.e., 92920, C9600, 
C9604, 92924, 92937, 92928, 92943, C9606, C9606, 92933, C9602, C9602, C9607) and 
DRG codes (i.e., DRG 246, DRG 247, DRG 248, DRG 249, DRG 250, DRG 251, DRG 273, 
DRG 274) indicated that the PCI procedure was performed during the episode index 
procedure.  
In contrast, only MS-DRG codes were used to identify CABG surgeries because 
CABG is performed only in inpatient settings. Among CABG episodes, episodes were 
included when the DRG codes (i.e., DRG 231, DRG 232, DRG 233, DRG 234, DRG 235, 
DRG 236) indicated that CABG was performed during the index procedure. Although the 
inclusion and exclusion criteria in this study affected the sample size, the total number of all 
CABG and PCI episodes identified were (n=3,690).  
Variables and Measures  
The primary outcome variable for the study was total 90-day episode payment. The 
secondary outcome variables were the five payment components: (1) index procedure 
payment, (2) professional payment, (3) post-acute care payment, (4) readmission payment, 
and (5) pharmacy payment. All these payment variables were continuous variables and 
classified by the type of the performed index procedure, CABG surgery or PCI procedure 
(see Table 2). Instead of focusing on provider submitted charges, this study focused on the 
allowed amounts. The window of the 90-day post-discharge allowed for the evaluation of 
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healthcare services that may extend beyond 30-days after the initial CABG surgery or PCI 
procedure. All payment variables were measured in 2018 U.S. dollars. The Personal 
Consumption Expenditures Health (PCI-Health) Index was used for the analysis of 
healthcare expenditure across each year of the study (see Appendix D).[70] The PCI-Health 
Index was recommended by the Agency for Healthcare Research and Quality (AHRQ) and 
was found to be the appropriate price index to reflect healthcare expenses.[71]  
The study also included other variables that represented patient factors, operative 
factors, and postoperative factors and whose relationship with total episode payments was 
examined. The patient variables of interest were age, gender, region, health plan, insurance 
type (i.e., Medicare Advantage, commercial), and comorbidities presented at admission. Age 
was a continuous variable measured in years. Gender, health plan, and insurance type were 
binary variables. Region was a nominal variable that represented the patient regions of 
Texas. Comorbidities were determined based on the Charlson Comorbidity Index (CCI) 
scores (see Appendix C). The CCI score was calculated according to the scoring system 
established by Charlson which takes into account the associated weight for each comorbid 
condition.[72] For example, patients with a CCI score of zero indicated that they have no 
records of comorbidities. The variables of comorbid conditions were also measured as binary 
variables to understand the impact of each comorbidity on CABG and PCI episode payments.  
In addition, the study included operative factors that were related to a patient’s 
condition when the index procedure was performed. The CABG episodes of major 
complication and comorbidity DRGs (i.e., 231, 233, 235) at the index procedures were split 
from those without major complication or comorbidity DRGs (i.e., 232, 234, 236). This DRG 
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intensity variable was examined with the 90-day CABG episode payments and also used for 
the subgroup analysis. Conversely, the PCI episodes were stratified based on whether the 
index PCI was performed for an indication of acute myocardial infarction (AMI) or not. The 
diagnosis codes from the literature (see Appendix F) were followed for identifying PCI 
episodes with AMI.[64]  
Lastly, the study included two postoperative factors, which were length of stay and 
readmission stage. Length of stay was a continuous variable, measured in number of days 
from admission date to discharge date. Outpatient PCI episodes were given a length of stay 
of zero. Next, the readmission variable was a nominal variable, measured by the identifying 
period at which the first readmission had occurred. The readmission stage variable had four 
categories: non-readmitted patients, readmitted patients within 30 days, readmitted patients 
within 31 to 60 days, and readmitted patients within 61 to 90 days. As a result, three dummy 
variables were created for the readmission variable to be used in analyses of the regression 
models. Table 2 describes all these variables of interest as well as their measurements.  
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Table 2: Variable Measurement Matrix for CABG & PCI 




Primary Outcome Variables 
90-day CABG episode 
payment 
Total estimate of allowed amount episode, including index CABG 
hospitalization and 90 days after discharge and including all five payment 
components (index procedure payment, professional payment, post-acute 
care payment, readmission payment, pharmacy payment); all amounts 




90-day PCI episode 
payment 
Total estimate of allowed amount episode, including index PCI procedure 
and 90 days after discharge and including all five payment components 
(index hospitalization payment, professional payment, post-acute care 
payment, readmission payment, pharmacy payment); all amounts calculated 




Secondary Outcome Variables (Episode Payment Components) 
Index procedure 
payment 
Total estimate of allowed amount for index procedure or index procedure or 
hospitalization from admission date to discharge date, calculated based on 
the estimate of allowed amount of type of service variable in the dataset 
Aim 2 Continuous 
Professional services 
payment 
Total estimate of allowed amount for all professional services of the episode, 
calculated based on the estimate of allowed amount of type of service 
variable in the dataset 
Aim 2 Continuous 
Postacute care payment Total estimate of allowed amount for all post-acute care type of service of the 
episode window, calculated based on the estimate of allowed amount of type 
of service variable in the dataset 
Aim 2 Continuous 
Readmission payment Total estimate of allowed amount for readmitted patients within 90 days after 
index procedure discharge date, calculated based on the estimate of allowed 
amount of type of service variable in the dataset 
Aim 2 Continuous 
Pharmacy payment Total estimate of allowed amount for prescription drugs of the episode 
window, calculated based on the estimate of allowed amount of pharmacy 
claims of the dataset 
Aim 2 Continuous 
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Independent Variables  





Age Patient age in years derived by calculating the difference between the year of 
admission date and the year of birth 
Aim 1 Continuous 
Gender A code identifying the sex of the member at enrollment; 
0=male, 1=female 
Aim 1 Categorical  
Region Patient hospital referral region (HRR) of Texas identified according to 
patient zip code 
Aim 1 Categorical 
Myocardial infarction  Previous patient condition of myocardial infarction for a minimum of a 6-
month period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Congestive heart failure Previous patient condition of congestive heart failure for a minimum of a 6-
month period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Peripheral vascular 
disease 
Previous patient condition of peripheral vascular disease for a minimum of a 
6-month period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Cerebrovascular disease Previous patient condition of cerebrovascular disease for a minimum of a 6-
month period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Dementia Previous patient condition of dementia for a minimum of a 6-month period 
prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Chronic pulmonary 
disease 
Previous patient condition of chronic pulmonary disease for a minimum of a 
6-month period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Rheumatologic disease Previous patient condition of rheumatologic disease for a minimum of a 6-
month period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Peptic ulcer disease Previous patient condition of for a minimum of a 6-month period prior the 
index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Mild liver disease Previous patient condition of mild liver disease for a minimum of a 6-month 
period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Diabetes without 
chronic complications 
Previous patient condition of diabetes without chronic complications for a 
minimum of a 6-month period prior the index procedure admission date; 
0=No, 1=Yes 
Aim 1 Categorical  
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Diabetes with chronic 
complications 
Previous patient condition of diabetes with chronic complications for a 
minimum of a 6-month period prior the index procedure admission date; 
0=No, 1=Yes 
Aim 1 Categorical  
Hemiplegia or 
paraplegia 
Previous patient condition of hemiplegia or paraplegia for a minimum of a 6-
month period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Renal disease Previous patient condition of Renal disease for a minimum of a 6-month 
period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Any malignancy, 
including lymphoma 
and leukemia, except 
malignant neoplasm of 
skin 
Previous patient condition of any malignancy, including lymphoma and 
leukemia, except malignant neoplasm of skin for a minimum of a 6-month 
period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Moderate or severe liver 
disease 
Previous patient condition of moderate or severe liver disease for a minimum 
of a 6-month period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Metastatic solid tumor Previous patient condition of metastatic solid tumor for a minimum of a 6-
month period prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
AIDS/HIV Previous patient condition of AIDS/HIV for a minimum of a 6-month period 
prior the index procedure admission date; 0=No, 1=Yes 
Aim 1 Categorical  
Charlson Comorbidity 
Index (CCI) score  
A weighted score of previous patient conditions for a minimum of a 6-month 
period prior admission date, adapted from the Charlson Comorbidity Index 
(see Appendix C) 
Aim 1 Continuous 
Health plan This variable identifies the type of fee-for-service plan (i.e., PPO, POS); 
0=PPO, 1=POS 
Aim 1 Categorical  
Insurance type This variable identifies the type of business (i.e., commercial, Medicare 
Advantage) the product is intended to serve; 0= commercial, 1=Medicare 
Advantage  
Aim 1 Categorical 
Zip code Patient’s 5-digit zip code at enrollment  Aim 1 Categorical 
Length of stay (LOS) Identifies the length of stay in days for index procedure; LOS = Date of 
Discharge – Date of Admission, 0=Outpatient PCI episodes  
Aim 1 Continuous 
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Readmission range Identifies the 1st all-cause readmission of patients within the 90-days period 
post-discharge, was coded as follows: 
• 0=no readmission 
• 1=within 30-day period post-discharge 
• 2=within 31- 60-day period post-discharge 
• 3=within 61- 90-day period post-discharge  
For the regression model analyses, three dummy variables were created (i.e., 
readmission1, 0=No, 1=Yes; readmission2, 0=No, 1=Yes; readmission3, 
0=No, 1=Yes) 
Aim 1 Categorical 
CABG DRG intensity Identifies the CABG episodes where the severity of the diagnosis 
reported during the index CABG hospitalization included major complication 
or comorbidity (MCC) (i.e., MS-DRGs with MCC: 231, 233, 235; MS-DRGs 




AMI PCI Identifies the PCI episodes where patients admitted for AMI and treated with 




Note: The primary source of data for the study variables was Optum claims data 
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; PPO, proffered provider organization; POS, point of service plan; MS-DRG, Medicare 
severity diagnosis-related group; MCC, major complication or comorbidity; AMI, acute myocardial infarction. 
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Data Sources 
This research used three different data sources. First, the key data source for this 
study was the Optum Clinformatics® DataMart (CDM): administrative claims data. Claims 
data have been essential source of information for studies of medical procedure cost analysis 
and financial burden of illness. Using claims data is a common approach for tracking and 
detecting medical costs of health care procedures for a large population of patients. The 
claims data used for this research creates standardized costs and does not reflect the actual 
payment. As a result, the claims data standardizes payment in the data set so as not to be 
impacted by contract discounting. These standardized costs allowed for making proper 
comparisons of payments across Texas by removing variation in negotiated prices between 
the insurer and healthcare providers. The claims dataset used for this research included 
patient demographic factors (i.e., age, gender, region) as well as clinical characteristics such 
as ICD-9/ICD-10 diagnoses that could be used to detect comorbid conditions across 
individuals over time. In addition, the claims data included date of services, type of services, 
patient zip codes, and dollar amounts associated with rendered procedures (see Appendix E). 
The claims datasets for this study were obtained through the University of Texas School of 
Public Health (UTSPH), which had signed an agreement for the creation of the research.  
Second, publicly available data from the Dartmouth Atlas of Health Care was used 
for Texas hospital referral regions (available at 
http://www.dartmouthatlas.org/tools/downloads.aspx?tab=39). The Dartmouth zip code to 
HSA to HRR crosswalk, allowed the aggregation of data at the zip code level to the HRR 
level in Texas and the grouping of patients into relevant geographic regions in the state.[29]  
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Third, the United States Census Bureau geospatial data (i.e., shapefiles) were also 
used in a geographic information system (GIS) software for this research.[73] The 
cartographic boundary shapefile for states was used to describe the patterns of CABG and 
PCI costs across Texas. These data were matched to the HRRs form the crosswalk data 
obtained by the Dartmouth Atlas of Health Care. Non-spatial tables of CABG and PCI 
episode payments to were joined with the spatial table based on HRRs ID field. The United 
States Census Bureau data were publicly available (which can be downloaded from 
https://www.census.gov/geo/maps-data/data/tiger.html ). They are spatial extracts from the 
Census Bureau's MAF/TIGER database, containing the U.S. geographic areas, which were 
used to create the desired maps and to display the spatial patters of payments for this study 
using ESRI ArcGIS software version 10.6. 
Data Analysis 
The descriptive statistics for the study episodes were calculated from the two primary 
payment variables, which were 90-day CABG episode payment and 90-day PCI episode 
payment, and then were compared. The distribution of continuous variables was presented by 
calculating their means and standard deviations as well as their medians and interquartile 
range values. The distribution of categorical variables was presented as raw counts and 
percentages. Statistical inference was conducted using t-tests with alpha = 0.05.  
For Aim 1, the study provided descriptive statistics that included the characteristics of 
the CABG or PCI episodes of the study population. Frequencies and percentages were 
calculated for region, gender, comorbidities, health plan, insurance type, and readmission 
stage variables. Means, medians, standard deviations, and interquartile ranges were 
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calculated for age, length of stay, and CCI score variables. The tests of comparisons between 
CABG and PCI episodes of the study population were Fisher’s exact tests for binomial 
variables, Chi-square (x2) tests for nominal variables, and independent samples t-test for ratio 
variables.  
In addition, an exploratory spatial data analysis (EDSA) approach was used to reveal 
and visualize variations of CABG and PCI episode payments across patient HRRs in Texas. 
All zip codes of Texas HRRs were identified using Dartmouth crosswalk data. Then, patient 
zip codes (i.e., patient’s 5-digit zip code at enrollment) were associated with the Texas’ 
HRRs zip codes and HRR map layers to reflect the geographic units of analysis and to define 
Texas regional healthcare markets (see Figure 2). This study used HRRs as the geographic 
unit of analyses because each HRR represented a healthcare market and had at least one city 
with a hospital where major surgical procedures such as CABG surgeries and PCI procedures 
are performed.[29] Patient zip codes were used for the current study to identify geographic 
unit of analysis instead of hospital zip codes because the claims data did not provide 
healthcare provider zip codes. The current study focused on patient level factors and patient 
zip codes were considered at patient levels. Furthermore, according to the DAHC, when 
patients in the U.S. are admitted to healthcare settings, the admission commonly takes a place 
within a close area where patients live and that provide proper level of care.[29]   
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The 90-day episode payment was the unit of cost. Episode payments were calculated 
in 2018 U.S. dollars for commercially insured patients who underwent CABG or PCI 
procedures in Texas HRRs. The episode period started from admission date and ended on the 
90th day post-discharge within the study timeline of 2014 to 2018. Winsorization was applied 
to each of the CABG and PCI episode payments at the 1st and 99th percentiles to minimize 
the influence of outliers. As a result, episode payments above the 99th percentile were 
adjusted to the payment value of the 99th percentile, and episode payments below the 1st 
percentile were adjusted to the payment value of the 1st percentile. 
Summary statistics were provided for CABG or PCI episodes across Texas HRRs. 
Means, quartiles, and standard deviations were calculated for the outcome variables. Two 
tables were provided to demonstrate the variability in total 90-day episode payments among 
patient HRRs in Texas for both CABG and PCI episodes. ANOVA tests were used to 
compare the mean values of the variables. Furthermore, Kruskal-Wallis tests were run to 
compare the median values of the variables. All these statistics tests were performed as 
comparative statistics to compare episode payments in terms of the patient characteristics, for 
example, comparing the mean episode payments between males and females. Pearson 
correlation coefficients were also calculated to explore the relationship between the 
continuous independent variables with the outcome variables. These tests provided an 
understanding about the strength as well as the directions of these relationships. In addition, 
comparisons were performed to measure degree of associations through chi-square and phi 
coefficient tests (p <0.05). 
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This study used the comorbidity variables as a measure of the burden of disease on 
the study population.[72, 74, 75] Patient comorbidities were identified according to diagnosis 
codes. To ensure the stability of the analyses in the regression models, the comorbidities that 
appeared in fewer than 20 episodes were not considered. For example, the peptic ulcer 
disease variable was not included in the regression model of predictors of episode payments 
for CABG procedures because there were only 5 episodes with this comorbid condition. A 
similar approach has been previously performed in the literature for comorbidities in 
regression analysis.[76] Furthermore, this study considered the six main regions of Texas for 
the analyses of the regression models and all of the remaining ones were collapsed into one 
region.  
The Least Absolute Shrinkage and Selection Operator (LASSO) method was used to 
select and simplify the number of covariates to include in the regression model.[76] Moreover, 
LASSO was performed to select significant predictors of episode payments following a 
similar approach that was used in previous clinical outcomes studies.[77, 78] Variables included 
in the LASSO method analyses were gender, age, comorbidities that have appeared in fewer 
than 20 episodes, length of stay, insurance type, regions, and readmission stage. A DRG 
intensity variable was also included for the CABG LASSO analysis. A recent study (2019) 
showed that patients who had complications during their index CABG procedure would 
significantly impact costs.[79] Also, an AMI PCI variable was included for the PCI LASSO 
analysis. The LASSO variables were used on all predictors for log transformed payments of 
CABG and PCI episodes. The log transformation was performed to normalize the payment 
data as they were found to be positively skewed. In addition, a previous study that compared 
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the performance of different regression models for analyzing cost of CABG surgery 
suggested that using log transformed cost data demonstrate good consistency in identifying 
factors that are significantly associated with increased cost.[80] After completing the LASSO 
analysis, the regression models with the LASSO set of variables were performed. 
The linear regression models were run to examine the impact of patient characteristics 
on the 90-day episode payments for each of the two selected procedures, CABG and PCI. 
The regression analyses provided insight into the impact of patient characteristics and other 
covariates on 90-day CABG and PCI episode payments in Texas using the following episode 
payment measurement equation: 
Log(Y) = ẞ0 + ẞ1X1 + … +ẞkXk +Ꜫ.   (1) 
The regression models were fitted to predict the log-normalized payment and 
investigated to determine the influence of patient factors, where Y is the logarithmic episode 
payment variable, ẞ0 is the intercept term, ẞ is the constant regression coefficient, X is the 
explanatory variable , k is the number of explanatory variables, and Ꜫ is the residual error. In 
addition, collinearity was diagnosed by calculating the variance inflation factor (VIF <10), 
and tolerance (T > 0.1).[81] Finally, the exponentiated coefficients were calculated from the 
regression models to see if and how patient characteristics significantly predicted episode 
payments. The predominant predictors of payments were further inspected. Finally, the most 
common causes of readmissions were identified, as well as the readmission rates by patient 
regions.  
For Aim 2, this study provided descriptive statistics: including summary tables for the 
episode payment and the drivers of payment variation across Texas. The episode payment 
37 
was disaggregated into five payment components, which were index procedure, professional 
services, post-acute care, readmission, and pharmacy. This study measured and described 90-
day mean episode payments, mean component payments, and mean subcomponent payments 
for both CABG surgeries and PCI procedures.  
As the 90-day episode payment was categorized into five components, these 
components were classified using two criteria, which were type of service and date of 
service. This information was available in the claims data that were used for this research. 
Index procedure payment included the total allowed amounts for inpatient facility care and 
surgery facility services for the period from the index procedure admission date to the 
discharge date, and although proceeded the 90 days post procedure were included in the 
episode period. Professional service payments included the total allowed amounts for any 
professional services during the episode period. Post-acute care payments included the 
allowed amounts for any ancillary and facility services during the episode period, not limited 
to care related to CAD. The readmission payment component included the total allowed 
amounts for any readmissions during the 90-day post-discharge period. For readmission stays 
longer than the 90 days, payments were cutoff at 90 days. This approach of calculating 
readmission payments was used in two similar previous studies.[51, 64] Finally, pharmacy 
payments included total reimbursements for pharmacy claims during the episode of care. 
Inpatient pharmacy costs were included in the inpatient payments. 
Furthermore, the study identified subcomponents for professional services as well as 
for post-acute care. The professional services were categorized into nine subcomponents, 
including evaluation and management (E&M), anesthesia, laboratory, emergency room, 
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diagnostic testing, physical medicine/rehab, radiology, surgery, and professional other. Post-
acute care services were also categorized into nine subcomponents, including home 
health/hospice visits, ancillary, rehab/skilled nursing facility, outpatient facility surgery, 
outpatient facility laboratory, outpatient facility diagnostic, emergency room, and outpatient 
facility other. This study examined the episode payment, which is broken down and 
summarized in Figure 3.
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1. Home Health/Hospice Visits 
2. Ancillary  
o Services and Supplies 
o Durable Medical Equipment 
o Administered Drugs 
o Transportation Services 
 
1. E&M 
o Office Visits 
o Consultations 
o Inpatient Visits 
2. Anesthesia 
3. Laboratory 
4. Emergency Room 
5. Diagnostic Testing 
6. Physical Medicine/Rehab 
7. Radiology 
8. Surgery 
9. Professional Other 
o Allergy Tests and Injections 
o Immunizations and Injections 
o Mental Health 
o Pathology 
o Preventive Medicine 
o Obstetrics 
o Vision, Hearing and Speech 
3. Rehab/Skilled Nursing Facility 
4. Outpatient Facility Surgery 
5. Outpatient Facility Radiology 
6. Outpatient Facility Laboratory 
7. Outpatient Facility Diagnostic 
8. Emergency Room 
9. Outpatient Facility Other 
 




o Post-discharge Inpatient Facility 
 
*Total allowed amount for facility inpatient and facility surgery services for the period from index admission date to discharge date 
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The differences in mean episode payments among low-payment versus high-payment 
hospitals were examined. As a result, hospitals were classified into four quartiles according 
to the 90-day mean episode payments for each CABG and PCI episodes. After that, the mean 
payments of each component (i.e., index payment, professional services payment, post-acute 
care payment, pharmacy payment, readmission payment) between the high- and low-payment 
quartiles were compared to determine which component contributed to the greatest 
proportion of variation. The rates of payment variations between high- and low-payment 
hospitals for both CABG and PCI episodes were calculated as well as demonstrated and 
displayed in bar charts. The absolute differences of payments between high-payment and 
low-payment quartiles were calculated for each of the payment components and for the 
subcomponents. Then, key drivers of payment variation were determined by calculating the 
degree to which variation in component payments attributable to the total variation in 90-day 
episode payments between high- and low-payment quartiles. The rate of total payment 















X 100.  (2)                   








The study then described the payment components of the five hospitals with the 
highest episode payments by examining payments in each component at the individual 
facility level to their payment variation. These five hospitals were ordered from the highest to 
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the lowest mean total episode payment and compared with the quartile hospitals and highest 
quartile hospitals. These comparisons were performed to observe the payment patterns for 
the highest payment hospitals for CABG surgeries and PCI procedures.  
After this, two subgroup analyses were performed for the CABG episodes and two 
subgroup analyses were performed for the PCI episodes. These analyses examined the 
robustness of the calculation method and the results of the model. First, for CABG episodes, 
a DRG intensity subgroup (i.e., episodes without major complication and comorbidity for the 
index hospitalization) was created to determine if DRG intensity affected the results. 
Furthermore, a commercial-only patient subgroup was created because they represented a 
high proportion of the study population (83%) and to ensure the results did not vary by 
insurance type. A similar approach has been performed in a previous study on CABG 
episode payments selecting a subgroup analysis of Medicare-only beneficiaries as they had a 
higher proportion of the study population (>75%) than the privately insureds.[51] Moreover, 
the same approach was followed for performing the subgroup analyses of PCI episodes. First, 
an AMI PCI subgroup (i.e., patients admitted for AMI and treated with PCI) was created to 
determine if AMI episodes affected the results. Second, a commercial-only patient subgroup 
was created as these patients represented a high proportion (84%) of the present study 
population. After that, hospitals were ranked within each subgroup by their mean 90-day 
episode payment and categorized into high-payment and low-payment quartiles to calculate 
the payment component variation. These subgroup analyses would enhance the 
understanding of the sources and magnitudes of payment variations. They would also help to 
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ensure that the calculations had reasonable validity and provided insights into how episode 
payment varied across Texas. 
Finally, this study examined differences in mean episode payments among low-
payment versus high-payment regions (assuming that patients performed their index 
procedure within their regions). Having the HRR as the geographic unit of analysis, HRRs 
were categorized into four quartiles based on each region’s 90-day mean episode payments. 
Two visual display maps were provided of the mean episode payments across the Texas 
HRRs using ArcGIS software. Episode payments were evaluated to compare high-payment 
versus low-payment regions, including the mean of each payment component (i.e., procedure 
payment, professional services payment, post-acute care payment, readmission payment, 
pharmacy payment) between the high- and low-payment quartiles. The absolute differences 
between high-payment and low-payment regions were calculated for the payment 
components. Then, the rate of total payment variation contributed was calculated for each 
payment component. This was done to determine which component contributed (%) the 
greatest proportion of variation. Statistical analyses were performed using SAS software 
version 9.4, Microsoft Excel version 16.23, and ArcGIS version 10.6. 
Ethical Considerations 
All claims data for this study were de-identified, and there was no harm to human 
subjects, qualifying this study for the Institutional Review Board (IRB) exemption. After 
seeking IRB exemption (IRB Number: HSC-SPH-19-0270), all the necessary requirements 
of the UTHealth Center for Healthcare Data were completed and submitted to gain access to 
the dataset. All data were stored on secure servers within the UTHealth SPH. Access was 
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obtained to the extracted datasets of interest through a UTHealth virtual private network, 
further ensuring data security. After confirming the proper study design and data 
management, this study was carried out. 
RESULTS 
The starting number of patients who underwent CABG surgeries and PCI procedures 
were 4,623 and 14,182, respectively. After applying the inclusion and exclusion criteria, a 
total of 999 CABG episodes were identified for 996 patients and a total of 2,691 PCI 
episodes were identified for 2,506 patients across the state of Texas from 2014 to 2018 (see 
Figure 4). The number of PCI episodes was 69.4% higher than the number of CABG 
episodes. Of the 996 identified patients who underwent CABG surgeries, there were 993 
patients with one episode and 3 patients with two episodes. On the other hand, of the 2,594 
identified patients who underwent PCI episodes, there were 2,506 patients with one episode, 
81 patients with two episodes, 6 patients with three episodes, and 1 patient with five 
episodes. All patients with multiple episodes were included in the study. As a result, a total 
of 3690 episodes were identified: a total of 999 CABG episodes and a total of 2691 PCI 
episodes.
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Figure 4: Exclusion Criteria for PCI and CABG Episodes 
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As shown in Table 3, the average age of the CABG episode patients was 61 years, 
and the average age of the PCI episode patients was 58.6 years for a difference of 2.4 years 
(p <0.0001). The variable age was normally distributed for both CABG and PCI episodes. 
There was a significant difference in the distribution of gender (i.e., male, female) in the 
CABG and PCI episodes (p =0.0038). However, the proportions of male episodes were 
higher than female episodes in both CABG (80.09%) and PCI (76.4%) episodes. Seventeen 
comorbid conditions were identified for the study population. The statistically significant 
differences in the proportions of comorbidities between CABG and PCI episodes were found 
in myocardial infarction (22.62% vs. 15.87%, p <0.0001); congestive heart failure (15.22% 
vs. 12.34% , p = 0.0214); peripheral vascular disease (13.01% vs. 6.09%, p <0.0001); 
cerebrovascular disease (19.62% vs. 8.40%); diabetes without chronic complications 
(25.43% vs. 19.10%, p <0.0001); and diabetes with chronic complications (15.82% vs. 
9.07%, p<0.0001). Likewise, there was significant difference between the means of the 
Charlson comorbidity score of the CABG episodes and the PCI episodes (1.89 vs. 1.38, p 
<0.0001). These distributions were not different for the remaining characteristics of 
insurance type (i.e., Medicare Advantage, commercial) or health plan (i.e., PPO, POS). 
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Table 3: Characteristics of the Study Population, CABG & PCI Episodes 
Characteristic 
 CABG episodes PCI episodes P-Value 
 (n = 999) (n=2691)  
Age Mean (SD) 61.0 (8.6) 58.6 (10.9) <0.0001** 
 Median (IQR) 61 (12) 59 (13)  
Gender n (%)    
Male  808 (80.9%) 2056 (76.4%) 0.0038** 
Female  191 (19.1%) 635 (23.6%)  
Comorbidities* n (%)    
Myocardial infarction   226 (22.62%) 427 (15.87%) <0.0001** 
Congestive heart failure  152 (15.22%) 332 (12.34%) 0.0214** 
Peripheral vascular disease  130 (13.01%) 164 (6.09%) <0.0001** 
Cerebrovascular disease  196 (19.62%) 226 (8.40%) <0.0001** 
Dementia  5 (0.50%) 24 (0.89%) 0.2316 
Chronic pulmonary disease  154 (15.42%) 360 (13.38%) 0.1122 
Rheumatologic disease  23 (2.30%) 68 (2.53%) 0.6958 
Peptic ulcer disease  5 (0.50%) 22 (0.82%) 0.3153 
Mild liver disease  44 (4.40%) 113 (4.20%) 0.7837 
Diabetes without chronic 
complications 
 254 (25.43%) 514 (19.10%) <0.0001** 
Diabetes with chronic complications  158 (15.82%) 244 (9.07%) <0.0001** 
Hemiplegia or paraplegia  4 (0.40%) 15 (0.56%) 0.7960 
Renal disease  101 (10.11%) 231 (8.58%) 0.1500 
Any malignancy, including 
lymphoma and leukemia, except 
malignant neoplasm of skin 
 54 (5.41%) 139 (5.17%) 0.7710 
Moderate or severe liver disease  2 (0.20%) 9 (0.33%) 0.7377 
Metastatic solid tumor  9 (0.90%) 28 (1.04%) 0.1430 
AIDS/HIV  1 (0.10%) 3 (0.11%) 0.9256 
CCI score Mean (SD) 1.89 (2.03) 1.38 (2.00) <0.0001** 
 Median (IQR) 1(2) 1 (2)  
Insurance type n (%)   0.517 
Medicare Advantage  170 (17.02%) 434 (16.13%)  
Commercial insurance  829 (82.98%) 2257 (83.87%)  
Health plan n (%)   0.585 
PPO  175 (17.52%) 451 (16.76%)  
POS  824 (82.48%) 2240 (83.24%)  
*Comorbidities present in <20 episodes were not considered for the regression analyses. 
**Statistically significant at  = 0.05 level. 
CCI, Charlson comorbidity index; PPO, preferred provider organization; POS, point of service plan 
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Regions of the study population were presented in Table 4. The results showed that 
there was a significant difference in the distribution of CABG and PCI episodes by patient 
regions (p <.0001). Six regions of the study population accounted for the vast majority of 
episodes (i.e., 81% for CABG and 79% for PCI episodes). These six regions were Houston, 
Dallas, Austin, Fort Worth, San Antonio, and Corpus Christi.  
Table 4: Region of the Study Population, CABG and PCI Episodes 
 CABG episodes PCI episodes P-Value* 
Region (n = 999) (n=2691)  
Abilene 8 (0.80%) 57 (2.12%) <0.0001** 
Amarillo 12 (1.20%) 55 (2.04%)  
Austin 119 (11.91%) 287 (10.67%)  
Beaumont 19 (1.90%) 39 (1.45%)  
Bryan 5 (0.50%) 23 (0.85%)  
Corpus Christi 45 (4.50%) 68 (2.53%)  
Dallas 207 (20.72%) 518 (19.25%)  
El Paso 2 (0.20%) 26 (0.97%)  
Fort Worth 100 (10.01%) 301 (11.19%)  
Harlingen 10 (1.00%) 10 (0.37%)  
Houston 262 (26.23%) 670 (24.90%)  
Longview 14 (1.40%) 38 (1.41%)  
Lubbock 11 (1.10%) 67 (2.49%)  
McAllen 17 (1.70%) 26 (0.97%)  
Odessa 19 (1.90%) 38 (1.41%)  
San Angelo 10 (1.00%) 20 (0.74%)  
San Antonio 72 (7.21%) 273 (10.14%)  
Temple 17 (1.70%) 51 (1.90%)  
Tyler 29 (2.90%) 56 (2.08%)  
Victoria 7 (0.70%) 13 (0.48%)  
Waco 8 (0.80%) 45 (1.67%)  
Wichita Falls 6 (0.60%) 10 (0.37%)  
Note: Regions were identified according to patients 5-digit zip codes at enrollment 
*Test of comparison was Chi-square (X2) test. 
**Statistically significant at  = 0.05 level 
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The descriptive statistics of postoperative factors were presented in Table 5. There 
was significant difference between the means of length of stay of CABG episodes and PCI 
episodes (8.36 vs. 3.28, p <0.0001). Lastly, there was statistically significant difference in the 
proportion of readmission for CABG episodes and PCI episodes by the readmission stage (p 
<0.0001). 
Table 5: Postoperative Factors of the Study Population, CABG and PCI Episodes 
Characteristic 
 CABG episodes PCI episodes P-Value 
 (n = 999) (n=2691)  
Length of stay Mean (SD) 8.36 (4.43) 3.28 (4.34) <0.0001** 
 Median (IQR) 7 (4) 2 (1)  
Readmission stage n (%)   <0.0001** 
No readmission  860 (86.06%) 2283 (84.84%)  
within 30-D  68 (6.81%) 190 (7.06%)  
within 31- 60-D period  36 (3.6%) 116 (4.31%)  
within 61- 90-D period  35 (3.5%) 102 (3.79%)  
**Statistically significant at  = 0.05 level.     
Total 90-Day Episode Payments for CABG and PCI Procedures 
The statewide mean 90-day CABG episode payment over the study period was 
$81,330 (SD = $47,382), while the mean 90-day PCI episode payment was $53,842 (SD = 
44,603) (see Table 6). The median 90-day CABG episode payment over the study period was 
$69,056 (IQR = $42,162), while the median 90-day PCI episode payment was $39,376 (IQR 
= $35,873). The distributions of 90-day episode payments were highly positively skewed for 
both CABG surgeries and PCI procedures. The 25th percentiles of 90-day episode payments 
for CABG surgeries and for PCI procedures were $52,284 and $27,015, respectively. The 
75th percentiles of 90-day episode payments for CABG surgeries and for PCI procedures 
were $94,446 and $62,888, respectively. 
  
49 
Table 6: 90-Day Episode Payment Descriptive Statistics for CABG and PCI Procedures 
Measure CABG episodes PCI episodes 
Mean  $81,330   $53,842  
SE 1499 860 
Median  $69,056   $39,376  
SD  $47,382   $ 44,604  
Kurtosis 4.65 6.55 
Skewness 1.93 2.37 
IQR  $42162  $ 35,873 
25th percentile   $52,284  $27,015  
75th percentile  $94,446   $62,888  
Note: Winsorization was applied to episode payments at the 1st and 99th percentiles 
SE, standard error; SD, standard deviation 
 
Episode Payments by Patient Characteristics 
The mean 90-day CABG episode payments varied by patient factors, including health 
plan, insurance type, readmission stage, and certain comorbidities (see Table 7). There was a 
statistically significant difference between the mean 90-day CABG episode payment for 
Medicare Advantage and commercial patients (p <0.0001). Furthermore, the mean 90-day 
CABG episode payments were not all the same among the readmission stages (p <0.0001). 
For comorbidities, there was a statistically significant difference between the mean 90-day 
CABG episode payment for patients with prior cerebrovascular disease and patients without 
(p =0.003), for patients with prior diabetes with chronic complications and patients without 
(p =0.004), for patients with prior hemiplegia or paraplegia and patients without (p =0.015), 




Table 7: CABG Episode Payments in 2018 Dollars by Patient Factors, Texas 2014–2018 
Variable Mean (SD) Median (IQR) P Value* 
All  $81,330 ($47,382) $69,056 ($42162)  
Gender Male $79,848 ($45,177) $67,893 ($39,933) 0.57 
 
Female $87,596 ($55,455) $72,478  ($58,709)  
Health Plan POS $84,625 ($49,136) $71,822  ($42,948) <.0001**  
PPO $65,810 ($34,112) $56,977  ($31,396)  
Insurance type Commercial $84,626 ($49,208) $71,813  ($42,934) <.0001**  
Medicare Advantage $65,253 ($32,878) $56,960  ($31,248)  
Readmission stage No Readmission $74,294 ($40,451) $65,005  ($37,980) <.0001** 
 Within 30-day period $123,508 ($59,603) $102,738  ($93,315)  
 Within 31- 60-day period $122,175 ($64,937) $118,005  ($61,845)  
 Within 61-90-day period $130,237 ($64,642) $110,714  ($86,995)  
Comorbidity Myocardial infarction  $83,784 ($47,690) $70,394  ($50,178) 0.35  
Congestive heart failure $90,082 ($57,121) $73,408  ($60,809) 0.11  
Peripheral vascular disease $88,512 ($56,651) $72,493  ($46,538) 0.26  
Cerebrovascular disease $74,473 ($45,525) $63,931  ($40,799) 0.003**  
Dementia $52,228 ($17,104) $60,212  ($7,946) 0.15  
Chronic pulmonary disease $82,054 ($48,540) $67,515  ($48,886) 0.99  
Rheumatologic disease $85,731 ($62,639) $66,664  ($47,225) 0.94  
Peptic ulcer disease $70,007 ($24,960) $69,293  ($35,449) 0.81  
Mild liver disease $89,897 ($42,639) $83,968  ($57,394) 0.13  
Diabetes without chronic complications $77,953 ($41,536) $69,545  ($43,323) 0.30  
Diabetes with chronic complications $95,886 ($61,076) $76,734  ($57,467) 0.004**  
Hemiplegia or paraplegia $153,750 ($84,466) $126,431  ($106,772) 0.015**  
Renal disease $101,934 ($70,810) $75,401  ($111,934) 0.05**  
Any malignancy, including lymphoma 
and leukemia, except malignant 
neoplasm of skin 
$75,943 ($40,752) $66,404 ($37,030) 0.46 
 
Moderate or severe liver disease $42,416 ($25,716) $42,416  ($36,368) 0.12  
Metastatic solid tumor $94,811 ($45,650) $87,221  ($47,453) 0.27  
AIDS/HIV $89,108 
 
$89,108   0.68 
* p-value was calculated for log payment 
**Statistically significant at =0.05 level 
 
The mean 90-day CABG episode payments were calculated across patient regions 
(see Table 8). The p-value of the ANOVA test that was performed to test log transformed 
payments among patient regions was significant (p <0.05). Thus, the patient regions of Texas 
were not all the same for the mean 90-day CABG episode payments. The p-value of the 
Kruskal-Wallis test for CABG episode payments was significant (p = 0.0010), so there was 
sufficient evidence that the median 90-day CABG episode payment for insured patients of at 
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least one of the regions was different than those for insured patients of the other regions. 
Therefore, the median payments for patients of the 22 regions were not equal. 
Table 8: Variability in the 90-day CABG Episode Payments Among Patient Regions in 
Texas. Regions Ordered from the Lowest to the Highest Mean Episode Payment, Texas 
2014–2018  
Region Mean (SD) P Value* Median (IQR) P Value** 
All $81,330 ($47,382)  $69,056 ($42162)  
Beaumont  $95,325 ($59,084) <.0001***  $83,384 ($55,338) 0.001*** 
Fort Worth  $91,387 ($53,244)   $73,660 ($49,326)  
Harlingen  $89,115 ($78,655)   $61,238 ($50,450)  
Houston  $88,201 ($53,831)   $73,271 ($45,746)  
Longview  $88,192 ($43,755)   $67,320 ($40,943)  
Lubbock  $87,573 ($57,159)   $75,401 ($41,985)  
Bryan  $85,709 ($30,103)   $69,349 ($50,149)  
Dallas  $84,852 ($47,920)   $71,225 ($51,230)  
Abilene  $83,445 ($52,316)   $69,833 ($73,887)  
El Paso  $82,111 ($34,752)   $82,111 ($49,147)  
Waco  $81,154 ($39,438)   $70,240 ($57,513)  
Tyler  $78,210 ($43,518)   $61,377 ($37,111)  
San Angelo  $75,629 ($50,892)   $55,817 ($48,129)  
Corpus Christi  $75,600 ($41,431)   $65,201 ($33,069)  
San Antonio  $74,187 ($28,312)   $68,244 ($36,322)  
Odessa  $73,386 ($30,587)   $70,392 ($42,756)  
McAllen  $73,271 ($34,025)   $58,172 ($32,026)  
Temple  $72,378 ($28,482)   $66,487 ($23,110)  
Austin  $63,021 ($35,242)   $58,984 ($35,114)  
Amarillo  $60,376 ($44,494)   $49,217 ($20,879)  
Victoria  $59,946 ($10,724)   $61,722 ($20,823)  
Wichita Falls  $57,474 ($18,319)   $56,259 ($36,659)  
Note: Regions ordered from the lowest to the highest mean episode payment; regions were identified according to patients 5-digit zip codes 
at enrollment 
*P-value of one-way ANOVA test for log payment  
**P-value of Kruskal-Wallis test for log payment  
***Statistically significant at =0.05 level 
 
The mean 90-day PCI episode payments varied by patient factors, including health 
plan, insurance type, readmission stage, and certain comorbidities (see Table 9). There was a 
statistically significant difference between the mean 90-day PCI episode payment for 
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Medicare Advantage and commercial patients (p <0.0001). Furthermore, the mean 90-day 
PCI episode payments were not all the same among the readmission stages (p <0.0001). For 
comorbidities, there was a statistically significant difference between the mean 90-day PCI 
episode payment for patients with prior congestive heart failure and patients without (p 
<.0001), for patients with prior peripheral vascular disease and patients without (p =0.0004), 
and for patients with prior cerebrovascular disease and patients without (p =0.03). Also there 
was a statistically significant difference between the mean 90-day PCI episode payment for 
patients with prior peptic ulcer disease and patients without (p =0.05), for patients with prior 
mild liver disease and patients without (p <.0001), for patients with prior diabetes with 
chronic complications and patients without (p =0.004), and for patients with prior renal 
disease and patients without (p <.0001). Finally, there was a statistically significant 
difference between the mean 90-day PCI episode payment for patients with any malignancy, 
including lymphoma and leukemia, except malignant neoplasm of the skin and patients 




Table 9: PCI Episode Payments in 2018 Dollars by Patient Characteristics, Texas 2014–2018 
Variable Mean (SD) Median (IQR) P-Value* 
All  $53,841  ($44,604) $39,376 ($ 35,873)   
Gender Male $53,733  ($44,585) $38,931 ($35,812) 0.96 
 
Female $54,195  ($44,699) $40,349 ($36,028)  
Health Plan POS $55,308  ($45,376) $40,185 ($36,297) <.0001**  
 
PPO $46,561  ($39,807) $33,482 ($30,390)   
Insurance Commercial $55,236  ($45,266) $40,184 ($36,296) <.0001**  
 
Medicare Advantage $46,590  ($40,267) $33,223 ($30,132)   
Readmission stage No Readmission $46,625  ($35,792) $36,474 ($28,029) <.0001**  
 
Within 30-D $85,236  ($59,283) $67,939 ($55,837)   
 Within 31-D to 60-D $100,411  ($64,511) $80,226 (85,595)  
 Within 61-D to 90-D $103,930  ($68,351) $85,145 ($78,926)  
Comorbidities Myocardial infarction  $58,691  ($52,194) $40,779 ($44,678) 0.63 
 
Congestive heart failure $72,156  ($62,072) $49,651 ($62,700) <.0001** 
 
Peripheral vascular disease $68,916  ($60,266) $47,789 ($56,827) 0.0004** 
 
Cerebrovascular disease $64,260  ($57,407) $43,683 ($48,097) 0.03** 
 
Dementia $49,816  ($44,204) $34,396 ($33,707) 0.15 
 
Chronic pulmonary disease $60,550  ($52,830) $43,216 ($45,789) 0.09 
 
Rheumatologic disease $65,068  ($56,269) $43,994 ($55,355) 0.12 
 
Peptic ulcer disease $82,484  ($58,545) $81,335 ($101,178) 0.05** 
 
Mild liver disease $71,708  ($61,422) $47,257 ($55,971) <.0001** 
 
Diabetes without chronic 
complications 
$56,094  ($46,359) $39,802 ($37,993) 0.23 
 
Diabetes with chronic 
complications 
$78,731  ($66,099) $56,955 ($62,521) <.0001** 
 
Hemiplegia or paraplegia $54,327  ($51,297) $41,068 ($57,521) 0.34 
 
Renal disease $81,124  ($66,287) $58,562 ($76,429) <.0001**  
Any malignancy, including 
lymphoma and leukemia, except 
malignant neoplasm of skin 
$66,001  ($54,397) $50,178 ($47,917) 0.0004** 
 
Moderate or severe liver disease $82,350  ($76,950) $53,925 ($43,839) 0.11  
Metastatic solid tumor $74,911  ($60,628) $59,250 ($59,114) 0.014**  
AIDS/HIV $90,115  ($98,865) $44,687 ($181,401) 0.42 
* p value was calculated for log payment  
**Statistically significant at =0.05 level 
 
The mean 90-day PCI episode payments were calculated across patient regions. The 
p-value of the ANOVA test that was performed to test log transformed PCI payments among 
patient regions was significant (p <0.0001) (see Table 10). Therefore, the results showed the 
patient regions of Texas were not all the same for the 90-day PCI episode payments. 
Furthermore, the p-value of the Kruskal-Wallis test for PCI episode payments was significant 
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(p = 0.001), so there was sufficient evidence that the median 90-day PCI episode payment for 
insured patients from at least one of the regions was different than those for insured patients 
from the other regions. Thus, the median payments of the 22 regions were not equal. 
Table 10: Variability in the 90-day PCI Episode Payments Among Patient Regions in Texas. 
Regions Ordered from the Lowest to the Highest Mean Episode Payment, Texas 2014–2018 
Region Mean (SD) P value* Median (IQR) P value** 
All $53,842 ($44,604)  $39,376 ($35,873)  
San Angelo  $68,812 ($61,259) <.0001***  $45,316  ($56,930) <.0001*** 
Fort Worth $57,760 ($43,520)   $43,888 ($35,834)  
Dallas  $57,438 ($46,984)   $41,371  ($38,690)  
Longview  $57,075 ($58,198)   $34,273  ($39,733)  
Lubbock  $56,592 ($54,973)   $31,186 ($55,116)  
Tyler  $55,528 ($41,166)   $41,471 ($48,216)  
Houston  $55,398 ($47,203)   $39,677 ($35,070)  
San Antonio  $55,304 ($47,738)   $38,241 ($39,451)  
Bryan  $53,271 ($41,225)   $38,881 ($47,204)  
Amarillo  $52,873 ($33,400)   $44,787 ($39,009)  
El Paso  $50,532 ($28,079)   $41,936 ($31,712)  
Abilene  $50,031 ($41,692)   $34,798 ($35,934)  
Austin  $48,897 ($39,170)   $38,139 ($30,596)  
Victoria  $47,649 ($30,364)   $39,311 ($31,177)  
Temple  $47,242 ($38,119)   $34,449 ($32,719)  
Beaumont  $45,346 ($35,234)   $30,835 ($34,497)  
Waco  $44,971 ($45,980)   $32,761 ($24,900)  
Harlingen  $43,893 ($31,219)   $36,139 ($38,990)  
Odessa  $43,693 ($27,789)   $37,204 ($31,732)  
McAllen  $40,515 ($24,192)   $29,597 ($22,464)  
Corpus Christi  $36,919 ($24,463)   $32,854 ($23,281)  
Wichita Falls  $27,283 ($9,871)   $24,957 ($15,892)  
Note: Regions ordered from the lowest to the highest mean episode payment; regions were identified 
according to patients 5-digit zip codes at enrollment 
*P-value of one-way ANOVA test for log payment  
**P-value of Kruskal-Wallis test for log payment  
***Statistically significant at =0.05 level 
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Correlation Coefficient Test Statistics  
Correlation coefficients were calculated between the dependent variables (i.e., 90-day 
CABG episode payments and 90-day PCI episode payment) and each of the independent 
continuous variables. Length of stay had a statistically significant positive and moderate 
linear relationships with 90-day episode payments for both CABG surgeries and PCI 
procedures (0.38 vs. 0.36, p <0.0001), meaning episode payments and length of stay tend to 
increase together. On the other hand, age had a statistically significant negative and weak 
linear relationship with 90-day episode payment for CABG surgeries ( -0.21, p <0.0001) but 
an insufficient correlation with PCI procedures (r <0.1). CCI score had a statistically 
significant weak and positive relationship with 90-day episode payments only for PCI 
procedures (r =0.17, p <0.0001) and had non-significant relationship with episode payments 
for CABG surgeries (p >0.05). 
In addition, this study diagnosed relationship by calculating phi correlation 
coefficients to perform comparisons between the type of insurance and health plan variables 
(see Table 11). Upon inspection of the phi coefficient results, a strong collinearity ( =0.9826 
, p <0.001) was found between the type of insurance product (i.e., commercial, Medicare 
Advantage) and the health plan (i.e., PPO, POS) for CABG episodes. A strong collinearity ( 
=0.9773 , p <0.001) was also found between the type of business the insurance product 
intended to serve and the health plan for PCI episodes. Furthermore, a strong collinearity was 
found ( =0.9788 , p <0.001) by combining all CABG and PCI episodes. As a result, there 
was a strong relationship between type of insurance and health plans. It was more likely that 
a Medicare Advantage patient had a PPO health plan than a POS plan. Also, it was more 
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likely that a commercial insurance patient had a POS health plan than a PPO health plan. 
Thus, one of these two variables needed to be removed from the LASSO selection technique 
to ensure the stability of the analysis. Accordingly, the health plan variable was removed.  
Table 11: Distribution of Health Plans according to the Type of Business the Health 
Insurance Product Intended to Serve (i.e., Medicare Advantage, Commercial) 







n ( %) 
Total P value 
Phi Coefficient 
() 
CABG Episodes      
POS 824 (%) 0 (0%) 824 <.0001** 0.9826 
PPO 5 (%) 170 (%) 175     
Total 829 170 999     
PCI Episodes      
POS 2240 (%) 0 (%) 2240 <.0001** 0.9773 
PPO 17 (%) 434 (%) 451     
Total 2257 434 2691     
All Episodes      
POS 3064 (%) 0 (%) 3064 <.0001** 0.9788 
PPO 22 (%) 604 (%) 626     
Total 3086 604 3690   
Note: the comparison was performed using chi-square, and phi coefficient tests 
**Statistically significant at =0.05 level 
Furthermore, the correlation between DRG intensity and patient comorbidities was 
inspected for CABG episodes (see Table 12). The results showed there was no significant 
evidence for collinearity for most comorbid conditions with the DRG intensity. However, 
there was a minor collinearity for a few comorbid conditions with the DRG intensity. There 
was a very weak collinearity between DRG intensity and myocardial infarction ( =0.1, p 
=0.0011), congestive heart failure ( =0.11, p =0.0008), and renal disease ( =0.13, p 
<0.0001). Consequently, none of these variables needed to be removed from the LASSO 
selection procedure for the regression model of CABG episodes.  
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Table 12: Distribution of Comorbidities according to CABG DRG Intensity for CABG 
Episodes 
Comorbidities Condition 
CABG DRG Intensity 








Myocardial infarction  Absence 506 267 773 0.0011** 0.1032 
Presence 121 105 226   
Congestive heart failure Absence 550 297 847 0.0008** 0.1061 
Presence 77 75 152   
Peripheral vascular disease Absence 555 314 869 0.0621 0.059 
Presence 72 58 130   
Cerebrovascular disease Absence 500 303 803 0.5114 -0.0208 
Presence 127 69 196   
Dementia Absence 622 372 994 0.0842 -0.0546 
Presence 5 0 5   
Chronic pulmonary disease Absence 539 306 845 0.1167 0.0496 
Presence 88 66 154   
Rheumatologic disease Absence 612 364 976 0.8054 -0.0078 
Presence 15 8 23   
Peptic ulcer disease Absence 624 370 994 0.8981 0.0041 
Presence 3 2 5   
Mild liver disease Absence 598 357 955 0.6588 -0.014 
Presence 29 15 44   
Diabetes without chronic complications Absence 468 277 745 0.95 0.002 
Presence 159 95 254   
Diabetes with chronic complications Absence 541 300 841 0.0182** 0.0747 
Presence 86 72 158   
Hemiplegia or paraplegia Absence 626 369 995 0.1175 0.0495 
Presence 1 3 4   
Renal disease Absence 582 316 898 <.0001** 0.1263 
Presence 45 56 101   
Any malignancy, including lymphoma and 
leukemia, except malignant neoplasm of skin 
Absence 593 352 945 0.975 -0.001 
Presence 34 20 54   
Moderate or severe liver disease Absence 625 372 997 0.2755 -0.0345 
Presence 2 0 2   
Metastatic solid tumor Absence 621 369 990 0.8077 -0.0077 
Presence 6 3 9   
AIDS/HIV Absence 626 372 998 0.4409 -0.0244 
Presence 1 0 1   
**Statistically significant at =0.05 level 
 
Statistical Tests for Normality and Data Transformation 
As shown in Figures 5 and 6, the distributions and probability plot for the 90-day 
payments were positively skewed for both CAGB and PCI episodes. By checking the 
distribution plot graphs and the QQ plot of log transformed payment variables, the 
transformation results were found to be satisfactory as they were normally distributed. 
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Figure 5: Assumption of Normality and the Log Transformation of CABG Episode Payments 
CABG Episode Payments 
 
 










Figure 6: Assumption of Normality and the Log Transformation of PCI Episode Payments 











Independent Predictors of 90-Day Episode Payments 
Table 13 showed the results of the LASSO performed on the independent variables 
for each of the three primary outcome variables, which were the 90-day CABG episode 
payment, the 90-day PCI episode payment, and the 90-day episode payment of all CABG and 
PCI episodes combined. The LASSO analysis resulted in small sets of variables of interest, 
with each set including fifteen variables. Within each set of variables, all the fifteen variables 
were included in the regression models. Three multiple linear regression models were used to 
examine the associations between patient factors and the 90-day episode payments for CABG 
surgeries, PCI procedures, and all CABG and PCI episodes combined.
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Table 13: LASSO Selection Summary for Episode Payments 
 CABG Episodes PCI Episodes All Episodes 















0 Intercept 0 0 Intercept 0 0 Intercept 0 0 
1 Length of Stay 0.0575 0.0565 Length of Stay 0.0481 0.0477 Length of Stay 0.1377 0.1375 
2 within 30-D 0.1135 0.1117 within 31-D to 60-D 0.0532 0.0525 within 30-D 0.1405 0.14 
3 Age 0.1787 0.1763 within 30-D 0.1391 0.1381 CABG Surgery 0.1725 0.1718 
4 within 31-D to 60-D 0.1826 0.1793 within 61-D to 90-D 0.1675 0.1662 within 31-D to 
60-D 
0.2282 0.2274 
5 Austin 0.2107 0.2067 Medicare Advantage 0.2155 0.2141 within 61-D to 
90-D 
0.24 0.239 
6 DRG Intensity 0.2296 0.2249 Renal disease 0.2174 0.2156 Medicare 
Advantage 
0.3038 0.3027 
7 within 61-D to 90-D 0.2327 0.2273 Diabetes with chronic 
complications 




8 Medicare Advantage 0.3322 0.3268 Age 0.2475 0.2453 Age 0.3243 0.3228 
9 Diabetes with chronic 
complications 
0.3438 0.3378 Corpus Christi 0.2625 0.26 Renal disease 0.3301 0.3285 
10 Fort Worth 0.3456 0.3389 Fort Worth 0.2641 0.2614 Austin 0.3459 0.3441 
11 Peripheral vascular disease 0.3506 0.3434 Dallas 0.266 0.263 Corpus Christi 0.346 0.3441 
12 Cerebrovascular disease 0.3596 0.3518 Austin 0.2673 0.264 Fort Worth 0.3497 0.3476 
13 Dallas 0.3601 0.3516 Any malignancy, including 
lymphoma and leukemia, 
except malignant neoplasm 
of skin 
0.2693 0.2657 Dallas 0.3536 0.3513 
14 Congestive heart failure 0.361 0.3519 Mild liver disease 0.2726 0.2688 Mild liver 
disease 
0.355 0.3525 
15 Any malignancy, including 
lymphoma and leukemia, 
except malignant neoplasm 
of skin 
0.3627 0.3530* Diabetes without chronic 
complications 
0.2747 0.2707* Metastatic solid 
tumor 
0.3572 0.3546* 
*Optimal value of criterion       
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 For the first regression model (see Table 14), the predictor variables explained 
37.11% of the variation in the values of 90-day CABG episode payments (R2 =0.3711). By 
reviewing the tolerance and variance inflection values, there were no tolerance values that 
fell below 0.1 and there were no variance inflation values above the value of 10. As a result, 
there was no threat of multicollinearity indicated through the tolerance and variance inflation 
analyses. After controlling for all other variables, episode payments were 22.78% lower for 
Austin region patients than those for Houston region patients (p <0.0001). For every one-year 
increase in age, episode payments decreased by 1.25 % (p <0.0001). Episode payments were 
16.58% lower for Medicare Advantage patients than those for commercial patients (p 
<0.0001). Episode payments were 9.99% higher for patients with peripheral vascular disease 
than for other patients (p =0.0309). Episode payments were 7.04% lower for patients with 
cerebrovascular disease than for other patients (p =0.0479). Episode payments were 8.87% 
higher for patients who had intense DRGs (i.e., 231, 233, 235) at the time of index 
hospitalization than those for other patients (p =0.0051). For a one-day increase in length of 
stay, total episode payments increased by 4.30 % (p <0.0001). Episode payments for 
readmitted patients within 30-days, within 31-60-days, and within 61- 90-days were higher 
than those for non-readmitted patients by 55.08%, 37.77%, and 39.93%, respectively (p 
<0.0001). The remaining independent variables in the model had non-significant p values (p 
>0.05).   
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Table 14: Linear Regression Model of Predictors of Episode Payments for CABG Procedures  
Variable Coefficient SE t value Tolerance VI P Value Exponentiated Estimate* 
Intercept 11.5178 0.11352 101.46 . 0 <.0001  
Texas regions        
Houston Reference       
Austin -0.2585 0.04591 -5.63 0.84286 1.18644 <.0001** -22.78% 
Dallas 0.04211 0.03757 1.12 0.80416 1.24353 0.2626 4.30% 
Fort Worth 0.09129 0.04876 1.87 0.87034 1.14897 0.0615 9.56% 
Other Regions -0.0016 0.03894 -0.04 0.78556 1.27297 0.9672 -0.16% 
Age -0.01256 0.00188 -6.69 0.70909 1.41026 <.0001** -1.25% 
Type of insurance        
Commercial Insurance Reference       
Medicare Advantage -0.18134 0.04351 -4.17 0.69748 1.43374 <.0001** -16.58% 
Congestive heart failure 0.03502 0.03957 0.89 0.92302 1.0834 0.3763 3.56% 
Peripheral vascular disease 0.09524 0.04405 2.16 0.84866 1.17832 0.0309** 9.99% 
Cerebrovascular disease -0.07299 0.03685 -1.98 0.87075 1.14844 0.0479** -7.04% 
Diabetes with chronic complications 0.06266 0.03888 1.61 0.92644 1.0794 0.1073 6.47% 
Any malignancy, including lymphoma and 
leukemia, except malignant neoplasm of skin 
-0.0719 0.06092 -1.18 0.98237 1.01795 0.2382 -6.94% 
DRG Intensity        
No (without MCC) Reference       
Yes (with MCC) 0.08498 0.0303 2.81 0.86913 1.15058 0.0051** 8.87% 
Length of Stay 0.04208 0.00333 12.63 0.85485 1.16979 <.0001** 4.30% 
Readmission Stage        
No Readmission Reference       
within 30-D 0.43878 0.0498 8.81 0.94564 1.05748 <.0001** 55.08% 
within 31-D to 60-D 0.32044 0.0688 4.66 0.93546 1.069 <.0001** 37.77% 
within 61-D to 90-D 0.32878 0.07617 4.32 0.95047 1.05211 <.0001** 38.93% 
n= 999; R-Square: 0.3711; Adj R-Square: 0.3608; F-value: 36.21; P < 0.0001; VI, variance inflation; DRG, Diagnosis Related Groups 
* Exponentiated parameter estimates (EXP(Coefficient)-1) *100,  
**Statistically significant at =0.05 level 
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For the second regression model (see Table 15), the predictor variables explained 
27.92% of the variation in the values of 90-day PCI episode payments (R2 = 0.2792). There 
were no tolerance values that fell below 0.1 and there were no variance inflation values 
above the value of 10. As a result, there was no threat of multicollinearity indicated through 
the tolerance and variance inflation analyses. After controlling for all other variables, episode 
payments were 20.76% lower for Corpus Christi region patients than those for Houston 
region patients (p=0. 0017). Alternatively, episode payments for Fort Worth patients were 
8.55% higher than episode payments for Houston region patients (p=0. 0297). For every one-
year increase in age, episode payments decreased by 0.33% (p=0.0092). Episode payments 
were 26.4% lower for Medicare Advantage patients than those for commercial patients (p 
<0.0001). Episode payments were 15.77% higher for patients with diabetes with chronic 
complications than for other patients (p=0. 0008). Episode payments were 18.04% higher for 
patients with renal disease than for other patients (p=0.0002). For a one-day increase in 
length of stay, episode payments increased by 4.89% (p <0.0001). Episode payments for 
readmitted patients within 30-days, within 31-60-days, and within 61-90-days were higher 
than for non-readmitted patients by 69.05%, 62.96%, and 68.07%, respectively (p <0.0001). 




Table 15: Linear Regression Model of Predictors of Episode Payments for PCI Procedures 
Variable Coefficient SE t value Tolerance VI P Value Exponentiated Estimate* 
Intercept 10.58289 0.07282 145.33 . 0 <.0001  
Texas Regions 
       
Houston Reference       
Austin -0.0584 0.03856 -1.51 0.92877 1.07669 0.13 -5.67% 
Corpus Christi -0.23275 0.07395 -3.15 0.97681 1.02374 0.0017** -20.76% 
Dallas 0.05851 0.03058 1.91 0.90492 1.10507 0.0558 6.03% 
Fort Worth 0.08204 0.03772 2.18 0.93079 1.07435 0.0297** 8.55% 
Age -0.00329 0.00126 -2.61 0.69121 1.44674 0.0092** -0.33% 
Type of Insurance        
Commercial Insurance Reference       
Medicare Advantage -0.30656 0.03754 -8.17 0.69009 1.44908 <.0001** -26.40% 
Mild liver disease 
0.05958 0.05832 1.02 0.96162 1.03992 0.3071 6.14% 
Diabetes without chronic complications 
0.04648 0.02974 1.56 0.96259 1.03887 0.1182 4.76% 
Diabetes with chronic complications 
0.14646 0.04372 3.35 0.83461 1.19817 0.0008** 15.77% 
Renal disease 
0.16584 0.04454 3.72 0.84496 1.18349 0.0002** 18.04% 
Any malignancy, including lymphoma and 
leukemia, except malignant neoplasm of skin 
0.08409 0.05317 1.58 0.94988 1.05276 0.1139 8.77% 
Length of Stay 0.04771 0.00272 17.54 0.94499 1.05821 <.0001** 4.89% 
Readmission Stage 
       
No Readmission Reference       
within 30-D 0.525 0.04135 12.7 0.95816 1.04366 <.0001** 69.05% 
within 31-D to 60-D 0.48834 0.05324 9.17 0.90443 1.10566 <.0001** 62.96% 
within 61-D to 90-D 0.5192 0.06218 8.35 0.93298 1.07183 <.0001** 68.07% 
n= 2,691; R-Square: 0.2792; Adj R-Square: 0.2752; F-value: 69.09; P < 0.0001; VI, variance inflation; 
* Exponentiated parameter estimates (EXP(Coefficient)-1) *100,  
**Statistically significant at =0.05 level 
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For the next regression model (see Table 16), the predictor variables explained 
36.24% of the variation in the values of 90-day episode payments for both CABG and PCI 
procedures (R2 = 0.3624). There were no tolerance values that fell below 0.1 and there were 
no variance inflation values above the value of 10. As a result, there was no threat of 
multicollinearity indicated through the tolerance and variance inflation analyses. After 
controlling for all other variables, the model demonstrated that the 90-day episode payments 
were 34.63% higher for CABG episode patients than those for PCI episode patients (p 
<0.0001). Total episode payments were 11.49% lower for Austin region patients than those 
for Houston region patients (p <0.0001). Total episode payments were 13.28% lower for 
Corpus Christi region patients than those for Houston region patients (p =0.0086). Total 
episode payments were 4.99% higher for Dallas region patients than those for Houston 
region patients (p =0.046). Total episode payments were 8.02% higher for Fort Worth region 
patients than those for Houston region patients (p =0.0119). For every one-year increase in 
age, episode payments decreased by 4.8% (p <0.0001). Total episode payments were 24.13% 
lower for Medicare Advantage patients than for commercial patients (p <0.0001). Total 
episode payments were 12.13% higher for patients with diabetes with chronic complications 
than for other patients (p =0.0004). Total episode payments were 13.07% higher for patients 
with renal disease than those for patients without renal disease (p =0.0005). For a one-day 
increase in length of stay, total episode payments increased by 4.85 % (p <0.0001). Episode 
payments for readmitted patients within 30-days, 31-60-days, and 61-90-days were higher 
than for non-readmitted patients by 65.17%, 57.26%, and 61.74%, respectively (p <0.0001). 
The remaining independent variables in the model had non-significant p values (p >0.05). 
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Table 16: Linear Regression Model of Predictors of Episode Payments for Coronary Revascularization Procedures, CABG and 
PCI procedures 
Variable Coefficient SE t value Tolerance VI P Value Exponentiated Estimate* 
Intercept 10.69608 0.0611 175.05 . 0 <.0001  
Revascularization Procedure        
PCI Procedure Reference       
CABG Surgery 0.29733 0.02365 12.57 0.76777 1.30247 <.0001** 34.63% 
Texas Regions        
Houston Reference       
Austin -0.12201 0.03063 -3.98 0.92322 1.08317 <.0001** -11.49% 
Corpus Christi -0.14249 0.0542 -2.63 0.97239 1.0284 0.0086** -13.28% 
Dallas 0.0487 0.0244 2 0.90243 1.10812 0.046** 4.99% 
Fort Worth 0.07717 0.03066 2.52 0.93123 1.07385 0.0119** 8.02% 
Age -0.00477 0.00105 -4.53 0.70309 1.42228 <.0001** -0.48% 
Type of Insurance        
Commercial Insurance Reference       
Medicare Advantage -0.27616 0.02973 -9.29 0.70091 1.42671 <.0001** -24.13% 
Mild liver disease 0.06628 0.04608 1.44 0.98047 1.01992 0.1504 6.85% 
Diabetes with chronic complications 0.11451 0.03205 3.57 0.85064 1.17558 0.0004** 12.13% 
Renal disease 0.12288 0.03508 3.5 0.84169 1.18809 0.0005** 13.07% 
Metastatic solid tumor 0.16273 0.09275 1.75 0.99313 1.00692 0.0794 17.67% 
Length of Stay 0.04735 0.00216 21.92 0.75344 1.32725 <.0001** 4.85% 
Readmission Stage        
No Readmission Reference       
within 30-D 0.5018 0.03318 15.12 0.96173 1.0398 <.0001** 65.17% 
within 31-D to 60-D 0.45273 0.04356 10.39 0.91512 1.09275 <.0001** 57.26% 
within 61-D to 90-D 0.48085 0.05013 9.59 0.94413 1.05918 <.0001** 61.74% 
n= 3,690; R-Square: 0.3624; Adj R-Square: 0.3598; F-value: 139.19; P < 0.0001; VI, variance inflation;  
* Exponentiated parameter estimates (EXP(Coefficient)-1) *100,  
**Statistically significant at =0.05 level 
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This study further explored the readmission rates across main Texas regions for both 
CABG and PCI episodes (see Table 17). Readmission rates differed notably among patient 
regions. For CABG episodes across Texas, San Antonio had the lowest readmission rate 
(6.94%), while the category of Other Regions categories had the highest readmission rate 
(17.01%), followed by Dallas region (16.43%) (see Figure 7). For PCI episodes, Corpus 
Christi had the lowest readmission rate (8.82%), while Fort Worth had the highest 
readmission rate (16.94%).  
Table 17: 90-day Readmissions Rates, CABG and PCI Episodes 














Austin 119 9 7.56% 287 33 11.50% 
Corpus Christi 45 5 11.11% 68 6 8.82% 
Dallas 207 34 16.43% 518 84 16.22% 
Fort Worth 100 15 15.00% 301 51 16.94% 
Houston 262 38 14.50% 670 105 15.67% 
San Antonio 72 5 6.94% 273 43 15.75% 
Other Regions 194 33 17.01% 574 86 14.98% 
Total 999 139 13.91% 2691 408 15.16% 
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Figure 7: Readmission Rates by Patient Regions 
 
Note: Other regions: Abilene, Amarillo, Beaumont, Bryan, El Paso, Harlingen, Longview, Lubbock, McAllen, Odessa, San Angelo, Temple, Tyler, Victoria, Waco, and Wichita Falls;  
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This study also identified the five most common causes for 90-day readmissions for 
both CABG surgeries and PCI procedures by detecting the DRG codes used for readmissions 
(see Table 18). As shown in Table 18, the most common cause of CABG 90-day episode 
readmissions according the MS-DRG codes was DRG 857(4.71%), followed by DRG 603 
(3.66%), DRG 291 (3.14%), DRG 293 (2.62%), and DRG 863 (2.62%). Alternatively, the 
most common causes of PCI 90-day episode readmissions according to the MS-DRG codes 
was DRG 247(8.63%), followed by DRG 287 (4.75%), DRG 291(4.40%), DRG 246 
(3.70%), and DRG 236 (3.35%) (see Table 18).  
 Moreover, the five most common principal diagnoses (i.e., first field diagnoses) were 
identified based on the ICD9 and ICD10 coding systems for all causes of 90-day 
readmissions for CABG and PCI episodes (see Table 19). As shown in Table 19,the most 
common cause of CABG 90-day episode readmission was ICD9 code 99859 (5.15%), 
followed by ICD10 code T814XXA (5.15%), ICD10 code I214 (3.09%), ICD10 code J90 
(3.09%), and ICD10 code I2699 (2.06%). The most common cause of PCI 90-day episode 
readmission was ICD10 code I214 (5.72%), followed by ICD10 code I25110 (5.37%), 




Table 18: Most Common Causes of 90-day Readmissions of CABG and PCI Episodes, MS-DRGs 
CAGB Episodes PCI Episodes 
Percentage Code DRG Description Percentage Code  DRG Description 
4.71% 857 Postoperative & Post-Traumatic Infections with O.R. 
Procedure with CC 
8.63% 247 Percutaneous Cardiovascular Procedures with Drug-eluting 
Stent without MCC 
3.66% 603 Cellulitis without MCC 4.75% 287 Circulatory Disorders Except AMI, with Cardiac 
Catheterization without MCC 
3.14% 291 Heart Failure and Shock with MCC OR Peripheral 
Extracorporeal Membrane Oxygenation (ECMO) 
4.40% 291 Heart Failure and Shock with MCC OR Peripheral 
Extracorporeal Membrane Oxygenation (ECMO) 
2.62% 293 Heart Failure and Shock without CC/MCC 3.70% 246 Percutaneous Cardiovascular Procedures with Drug-eluting 
Stent with MCC or 4+ Vessels or Stents 
2.62% 863 Postoperative & Post-Traumatic Infections without 
MCC 
3.35% 236 Coronary Bypass without Cardiac Catheterization without 
MCC 
CC, complication or comorbidity; MCC, major complication or comorbidity; MS-DRG, Medicare severity diagnosis-related group 
 
Table 19: Most Common Principal Diagnoses of 90-day Readmissions of CABG and PCI episodes, ICD9 and ICD10 
CAGB Episodes PCI Episodes 
Percentage Code Description Percentage Code  Description 
5.15% 99859 Other postoperative infection 5.72% I214 Non-ST elevation (NSTEMI) myocardial infarction 
5.15% T814XXA Infection following a procedure, initial encounter 5.37% I25110 Atherosclerotic heart disease of native coronary artery with 
unstable angina pectoris 
3.09% I214 Non-ST elevation (NSTEMI) myocardial infarction 5.20% I2510 Atherosclerotic heart disease of native coronary artery 
without angina pectoris 
3.09% J90 Pleural effusion, not elsewhere classified 4.85% 41401 Coronary atherosclerosis of native coronary artery 
2.06% I2699 Other pulmonary embolism without acute cor 
pulmonale 
1.91% I110 Hypertensive heart disease with heart failure 
 
72 
Drivers of 90-Day Episode Payment Variations at the Hospital Level 
For CABG surgeries at the hospital level, 709 episodes performed in 64 hospitals 
across the state of Texas were identified after excluding episodes in hospitals with less than 
five episodes performed over the study period (see Table 20). Payment variation between 
high- and low- payment hospitals were considerable. The mean 90-day CABG episode 
payment for hospitals was $61,028 in the lowest payment quartile of spending vs. $106,148 
in the highest quartile, for a difference of $45,121 (74%). Payments for index procedure 
accounted for the largest share of total episode payment for CABG surgeries, ranging from 
56% to 62% across quartiles. 
All payment components for 90-day CABG episodes were higher in payments for the 
high-payment quartile than those for the low-payment quartile except for pharmacy (see 
Figure 9). In comparison to with the lowest payment quartile hospitals, the highest payment 
quartile hospitals had 58% higher index procedure payments ($59,851 vs. $37,946), 55% 
higher professional payments ($21,955 vs. $14,179), 105% higher post-acute-care payments 
($12,859 vs. $6,259), 796% higher readmission payments ($10,069 vs. $1,124), and 7% 
lower pharmacy payments ($1,414 vs. $1,519). Thus, payment difference between high- and 
low- payment hospitals for 90-day CABG episode payments was greatest for readmission 
payments, followed by post-acute care payments, index procedure payments, professional 
payments, and pharmacy payments. Thus, the study showed that the component with the 
highest difference rate between high- and low-payment hospitals was related to readmission 
(see Figure 14). 
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Within professional service payments, payments for surgery accounted for the 
majority of payments across quartiles. Within post-acute care payments, payments for 
“outpatient facility surgery” accounted for a significant proportion of payments and was a 
key driver 6.2% of payment variation (see Table 20). Readmission rates for 90-day CABG 
episodes differed significantly between low- and high-payment hospitals (8.90% for low-
payment hospitals vs. 14.92% for high-payment hospitals). 
As for the drivers of these differences, index procedure contributed 48.6% to the 
variation in total episode payments between high-payment and low-payment hospitals. 
Readmission, professional service, post-acute care, and pharmacy contributed to the variation 
in total episode payments between high-payment and low-payment hospitals by 19.8%, 
17.2%, 14.6%, and 0.23%, respectively (see Figure 9). Finally, for the five hospitals with the 
highest total 90-day CABG episode payments, the component that drove the higher payment 




Table 20: The Contribution of CABG Payment Components and Subcomponents to Total 
Episode Payment Variation between High- and Low-payment Hospitals 
*Hospitals that performed less than five episodes were excluded 

















1 (Lowest) 4 (Highest) $ % 
Pharmacy   $1,349   $1,519   $1,414   $105 0.23% 
Readmissions   $5,220   $1,124   $10,069   $8,945  19.82% 
Post-acute Care Home Health  $427   $263   $671   $408  0.90% 
Ancillary  $1,142   $869   $1,214   $345  0.76% 
Rehab/Skilled Nursing Facility  $597   $849   $615   $235 0.52% 
OP Facility Surgery  $1,278   $306   $3,133   $2,828  6.27% 
OP Facility Radiology  $259   $180   $180  - 0.00% 
OP Facility Laboratory  $190   $123   $169   $ 45  0.10% 
OP Facility Diagnostic  $298   $402   $263   $140 0.31% 
Emergency Room  $1,565   $1,432   $1,616   $184  0.41% 
OP Facility Other  $3,372   $1,835   $4,999   $3,164  7.01% 
Subtotal Post-acute Care  $9,128   $6,259   $12,859   $6,600  14.63% 
Professional E&M  $3,225   $2,327   $4,191   $1,864  4.13% 
Anesthesia  $5,776   $4,710   $7,099   $2,389  5.29% 
Laboratory  $139   $93   $133   $40  0.09% 
Emergency Room  $241   $213   $263   $50  0.11% 
Diagnostic Testing  $527   $442   $710   $268  0.59% 
Physical Medicine/Rehab  $110   $137   $104   $32 0.07% 
Radiology  $252   $205   $301   $96  0.21% 
Surgery  $7,231   $5,837   $8,834   $2,997  6.64% 
Professional Other  $303   $215   $321   $106  0.24% 
Subtotal Professional  $17,803   $14,179   $21,955   $7,777  17.24% 
Index Procedure   $48,886   $37,946   $59,851   $21,904  48.55% 
Total   $82,387   $61,028   $106,148   $ 45,121  100.00% 
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Figure 8: The Percentage of Differences between High- and Low-payment Hospitals for 
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Figure 9: CABG Payment Components and Variation of Average 90-Day Episode Payments among Hospital Payment Quartiles. 
The Contribution of Each Component to the Total CABG Episode Payment Variation between High- and Low-
payment Hospitals 
  
1 2 3 4
Pharmacy $1,518.85 $1,099.27 $1,364.31 $1,413.54
Readmission $1,124.21 $3,356.49 $6,331.83 $10,069.25
Postacute Care $6,259.49 $7,457.03 $9,937.15 $12,859.23
Professional Services $14,178.54 $16,478.70 $18,599.63 $21,955.45




































Table 21: CABG Episode Payment Components of Lowest Quartile Hospitals, Highest 











Hospital A Hospital B Hospital C Hospital D Hospital E  
Pharmacy $1,519 $1,414 $1,748 $1,564 $1,336 $1,938 $819 
Readmission $1,124 $10,069 $21,532 $43 - $34,359 - 
Post-acute Care $6,259 $12,859 $5,595 $23,142 $5,519 $6,088 $16,207 
Professional $14,179 $21,955 $17,580 $26,536 $27,081 $19,939 $22,738 
Index $37,946 $59,851 $80,514 $72,833 $79,836 $50,271 $70,081 




For PCI procedures at the hospital level, 2,132 episodes performed in 146 hospitals 
across the state of Texas were identified after excluding episodes of hospitals with less than 
five episodes preformed over the study period (see Table 22). Payment variations between 
high- and low-payment hospitals were considerable. The mean 90-day PCI episode payment 
for hospitals was $33,696 in the lowest payment quartile of spending vs. $74,510 in the 
highest quartile, for a difference of $40,814 (121%). Payments for index procedure 
accounted for the largest share of total PCI episode payment ranging from 47% to 60% 
across quartiles. 
All payment components for PCI episodes were higher in payments for hospitals in 
the high-payment than those for the low-payment quartile (see Figure 10). In comparison to 
the lowest payment quartile hospitals, the highest payment quartile hospitals had 75% higher 
index procedure payments ($35,201 vs. $20,137), 46% higher professional payments ($7,774 
vs. $5,308), 271% higher post-acute care payments ($20,023 vs. $5,402), 539% higher 
readmission payments ($9,879 vs. $1,546), and 25% higher pharmacy payments ($1,633 vs. 
$1,303). As a result, payment difference between high- and low- payment hospitals for 90-
day PCI episode payments was greatest for readmission payments, followed by post-acute 
care payments, index procedure payments, professional payments, and pharmacy payments. 
Readmission rates of 90-day PCI episodes differed significantly between low- and high- 
payment hospitals (9.32% for the low-payment hospitals vs. 15.30% for the high-payment 
hospitals). 
As for the drivers of these differences, index procedure and post-acute care 
components contributed to the variation in total episode payment between high-payment and 
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low-payment hospitals by about the same percentage (36.9% and 35.8%, respectively). 
Readmission, professional services, and pharmacy contributed to the variation in total 
episode payments between high-payment and low- payment hospitals by 20.4%, 6%, and 
0.81%, respectively (see Figure 11). Finally, among the five hospitals with the highest total 
PCI episode payments, the component that drove these higher payments varied from hospital 
to hospital (see Table 23). 
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Table 22: The Contribution of PCI Payment Components and Subcomponents to Total 
Episode Payment Variation between High- and Low-payment Hospitals 
*hospitals that performed less than five episodes were excluded.  
























Pharmacy   $1,472   $1,303   $1,633   $330  0.81% 
Readmissions   $4,393   $1,546   $9,879   $8,333  20.42% 
Post-acute Care Home Health  $143   $76   $112   $36  0.09% 
Ancillary  $2,883   $1,674   $5,685   $4,010  9.83% 
Rehab/Skilled Nursing Facility  $86   $45   $137   $92  0.23% 
OP Facility Surgery  $3,133   $1,126   $5,496   $4,370  10.71% 
OP Facility Radiology  $286   $218   $315   $96  0.24% 
OP Facility Laboratory  $198   $163   $330   $167  0.41% 
OP Facility Diagnostic  $668   $389   $601   $212  0.52% 
Emergency Room  $2,041   $1,184   $3,154   $1,970  4.83% 
OP Facility Other  $2,059   $525   $4,192   $3,667  8.98% 
 Total Post-acute Care  $11,496   $5,402   $ 20,023   $ 14,621  35.82% 
Professional E&M  $1,929   $1,698   $2,358   $660  1.62% 
Anesthesia  $448   $243   $456   $213  0.52% 
Laboratory  $148   $148   $163   $15  0.04% 
Emergency Room  $407   $345   $460   $114  0.28% 
Diagnostic Testing  $622   $458   $722   $264  0.65% 
Physical Medicine/Rehab  $22   $14   $18   $4  0.01% 
Radiology  $241   $166   $245   $80  0.20% 
Surgery  $2,651   $2,076   $3,079   $1,002  2.46% 
Professional Other  $212   $161   $274   $113  0.28% 
Total Professional  $6,678   $5,308   $7,774   $2,466  6.04% 
Index Procedure Inpatient Facility  $28,316   $20,137   $35,201   $15,064  36.91% 
Total   $52,355   $33,696   $74,510   $40,814  100.00% 
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Figure 11: PCI Payment Components and Variation of Average 90-Day Episode Payments among Hospital Quartiles. The 




1 2 3 4
Pharmacy $1,302.75 $1,359.27 $1,593.74 $1,632.86
Postacute Care $5,401.80 $8,447.91 $12,179.09 $20,022.59
Professional Services $5,308.40 $6,458.67 $7,163.28 $7,774.30
Readmission $1,546.36 $2,854.54 $3,361.70 $9,879.42






































Table 23: PCI Episode Payment Components of Lowest Quartile Hospitals, Highest Quartile 











Hospital A Hospital B Hospital C Hospital D Hospital E  
Pharmacy  $1,303   $1,633   $606   $1,084   $893   $2,196   $2,495  
Readmission  $1,546   $9,879   $53,999   $801   $7,320   $21,558   $22,755  
Post-acute Care  $5,402   $20,023   $51,235   $4,451   $41,410   $24,008   $18,235  
Professional  $5,308   $7,774   $14,829   $4,719   $9,387   $7,696   $7,287  
Index  $20,137   $35,201   $30,117   $97,412   $34,504   $34,266   $30,412  
Total Episode   $33,696   $74,510   $150,786   $108,467   $93,514   $89,723   $81,184  
Subgroup Analyses 
As shown in Table 24, for the CABG episode subgroup analyses, there were 381 
episodes where CABG surgery was performed for DRG type without major complication and 
comorbidities and 663 episodes where CABG surgery was performed for patients with 
commercial insurance. After reclassifying hospitals into payment quartiles within each 
subgroup, index procedures remained the main driver of payment variation within the CABG 
episode subgroups.  
For the PCI episode subgroup analyses, there were 1,469 episodes where a PCI 
procedure was performed for PCI with AMI and 1,952 episodes where a PCI procedure was 
performed for patients with commercial insurance. After reclassifying hospitals into payment 
quartiles within the two subgroups, for the AMI PCI subgroup, index procedures and post-
acute care were found to contribute to payment variation about the same amount. For the 
commercial PCI subgroup, index procedure was the main driver of payment variation.  
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Table 24: Payment Components and Variation of Average 90-Day Episode Payments for CABG and PCI Procedures between 
High- and Low-Payment Hospitals in the Subgroups 
Payment Component Low Payment Hospitals High Payment Hospitals Difference % Variation 
DRG Intensity CABG* (n=381)     
Index Procedure  $35,418   $54,385   $18,967  60% 
Post-acute Care  $5,400   $9,716   $4,316  14% 
Readmission  $1,399   $3,940   $2,541  8% 
Professional Services  $13,571   $19,840   $6,270  20% 
Pharmacy  $1,675   $1,268   $407 -1% 
  Total Episode Payment  $57,462   $89,150   $31,687        
Commercial CABG (n=663)     
Index Procedure  $39,416   $63,295   $23,878  52% 
Post-acute Care  $5,424   $11,857   $6,434  14% 
Readmission  $1,251   $10,991   $9,740  21% 
Professional Services  $14,794   $ 21,399   $6,605  14% 
Pharmacy  $1,758   $1,372   $(386) -1% 
  Total Episode Payment  $62,643   $108,915   $46,272   
     
AMI PCI (n=1,469)     
Index Procedure  $20,483   $35,987   $15,504  35% 
Post-acute Care  $5,178   $20,723   $15,545  35% 
Readmission  $958   $11,184   $10,225  23% 
Professional Services  $5,106   $8,146   $3,039  7% 
Pharmacy  $1,267   $1,608   $342  1% 
  Total Episode Payment  $32,992   $77,647   $44,655        
Commercial PCI (n=1,952)     
Index Procedure  $21,550   $36,114   $10,811  49% 
Post-acute Care  $4,750   $19,257   $7,250  33% 
Readmission  $1,011   $10,589   $2,179  10% 
Professional Services  $5,417   $7,756   $1,766  8% 
Pharmacy  $1,407   $1,714   $232  1% 
  Total Episode Payment  $34,136   $75,429   $22,238   
Note: hospitals were ranked from lowest to highest average 90-day episode payments and then categorized into low and high payment hospitals  
* Index CABG hospitalization without a major complication or comorbidity 
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Drivers of 90-Day Episode Payment Variations at the Regional Level 
Furthermore, two Texas maps were created to demonstrate the variability of episode 
payments visually across Texas regions ,which were identified according to patients 5-digit 
zip codes at enrollment, for both of CABG episodes and PCI episodes (see Figures 12 & 13).  
Figure 12: Texas Map with CABG Surgery Episode Payment Variation 
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Figure 13: Texas Map with PCI Episode Payment Variation 
 
For CABG surgeries at the regional level, 997 episodes were identified across Texas 
HRRs, excluding the El Paso region because it had less than five episodes over the study 
period (see Table 25). There was considerable payment variation between high- and low-
payment regions. The mean 90-day CABG episode payment for the identified regions was 
$62,639 in the lowest payment quartile vs. $90,444 in the highest quartile, for a difference of 
$27,805 (44.4%). Payments for index procedure accounted for the largest share of total 
episode payment for CABG surgeries ranging from 58.33% to 65.86% across quartiles. 
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All payment components for CABG episodes were higher in payments for the high-
payment quartile than those for the low-payment quartile. In comparison to the lowest 
payment quartile regions, the highest payment quartile regions had 35.75% higher index 
procedure payments ($52,753 vs. $38,861), 39.66% higher professional payments 
($17,501vs. $12,531), 12.73% higher post-acute care payments ($8,880 vs. $7,877), 312.53% 
higher readmission payments ($9,961 vs. $2,415), and 41.25% higher pharmacy payments 
($1,349 vs. $955). Thus, payment difference between high- and low- payment regions for 90-
day CABG episode payments was greatest for readmission payments.  
As for the drivers of these differences, index procedure contributed 49.96% to the 
variation in total episode payments between high- and low-payment regions. Readmission, 
professional service, post-acute care, and pharmacy contributed to the variation in total 
episode payments between high-payment and low-payment regions by 27.14%, 17.87%, 
3.61%, and 1.4%, respectively (see Table 25).  
Table 25: Payment Components and Variation of Average 90-Day Episode Payments for 





Regions Difference* % Variation 
     
CABG (n=997)     
 Index Procedure  38,861  52,753   13,892  49.96% 
 Post-acute Care  7,877  8,880   1,003  3.61% 
 Readmission  2,415  9,961   7,546  27.14% 
 Professional Services  12,531  17,501   4,970  17.87% 
 Pharmacy  955  1,349   394  1.4% 
  Total Episode Payment 62,639  90,444   27,805   
Note: El Paso region was removed because it had less than 5 episodes. Payments were estimated at regional level 
. *The absolute differences between high- and low-payment regions 
 
For PCI procedures at the regional level, 2,691 episodes performed in 22 HRRs 
across the state of Texas were identified (see Table 26). There was no single region with 
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fewer than five episodes over the study period. There was considerable payment variation 
between high- and low-payment regions. The mean 90-day PCI episode payment for all 
regions was $38,460 in the lowest payment quartile of spending vs. $59,535 in the highest 
quartile, for a difference of $21,075 (5%). Payments for index procedure accounted for the 
largest share of total episode payment for PCI procedures ranging from 49.11% to 57.85% 
across quartiles. 
Payments for PCI episodes were higher for regions in the highest payment quartile 
than those for the low-payment quartile across all payment components. In comparison to the 
lowest payment quartile regions, the highest payment quartile regions had 31.41% higher 
index procedure payments ($29,240 vs. $22,250), 26.17% higher professional payments 
($6,875 vs. $5,449), 85.08% higher post-acute care payments ($16,195 vs. $8,750), 463.11% 
higher readmission payments ($5,885 vs. $1,045), and 38.75% higher pharmacy payments 
($1,340 vs. $966). Thus, payment difference between high- and low-payment regions for 90-
day PCI episode payments was greatest for readmission payments. 
As for the drivers of these differences, index procedure 33.17% and post-acute care 
35% contributed relatively similar proportions to the variation in total episode payment 
between high-payment and low-payment regions. Readmission, professional services, post-
acute care, and pharmacy contributed 23%, 7%, and 2%, respectively to the variation in total 
90-day episode payments between high- and low- payment region (see Table 26). 
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Table 26: Payment Components and Variation of Average 90-Day Episode Payments for 





Regions Difference* % Variation 
     
PCI (n=2691)     
 Index Procedure   22,250   29,240   6,990  33% 
 Post-acute Care   8,750   16,195   7,444  35% 
 Readmission   1,045   5,885   4,840  23% 
 Professional Services   5,449   6,875   1,426  7% 
 Pharmacy   966   1,340   374  2% 
  Total Episode Payment  38,460   59,535   21,075   
Note: Payments were estimated at regional level 




With the CMS bundled payment models, including the 90-day clinical episodes of 
care related to 32 conditions and procedures,[34, 69] private payers began to use such models to 
drive improving patient outcomes and lowering healthcare costs.[42] The present study is one 
of the few that has estimated 90-day episode payments for CABG surgery and PCI 
procedures,[31, 51, 64] and it is the only one to be conducted for commercially insured patients 
across Texas. In addition, commercial insurance payment data, rather than charge data, of a 
representative commercially insured cohort was used in these analyses. Thus, it represents a 
vital contribution to the literature, and its results are expected to provide strategies for private 
payers as well as for healthcare providers that want to participate or implement bundled 
payments.  
As healthcare providers assume accountability for the quality and costs under bundled 
payment programs, there are some implementation challenges from the provider’s 
perspective as well as from the payer’s perspective. For example, there is a financial risk for 
hospitals based on the 90-day period following an invasive procedure since a majority of that 
period is for post-acute care. Therefore, a hospital, for example, that provides an index 
procedure might bear a financial risk for the type of care provided after discharge, especially 
if complications occur during the 90-day post-discharge period. Therefore, healthcare 
providers from different disciplines and in multiple healthcare settings will need to 
understand the financial risk areas around healthcare episodes to succeed under the episode 
payment model. This risk-sharing could encourage better communication and enhance care 
coordination among different healthcare settings responsible for the same episode of care. In 
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response, healthcare providers will need to provide better care and improve patient outcomes, 
which could be considered an advantage of the bundled payment model. 
The episode payment model might create additional challenges. It might be difficult 
to distribute payments among healthcare providers within the episode of care as these 
payments usually belong to different providers in multiple healthcare settings. For episode 
payments, one lump sum is reimbursed for all services related to the episode of care. Recent 
efforts for bundled payments explain that such issues may be significant barriers for 
implementing successful bundled payment.[44, 82] Nevertheless, some studies have found 
significant payment reductions for other surgical procedures after implementing the bundled 
payment model.[48, 49, 83]  
Studies conducted on CABG and PCI episodes using Medicare data demonstrated 
lower average payments of episodes than those episode payments from the present research 
findings.[51, 55, 59, 61, 64] This variation was expected and supported in the literature,[66, 84] which 
indicated that healthcare prices for commercially insured patients were substantially higher 
than those for Medicare fee-for-service patients. To a certain degree, this variation has 
occurred because Medicare pays healthcare providers based on a federally established 
formula rather than on negotiated payment rates or on reported provider charges.  Also, 
Medicare uses DRGs as the basis for inpatient payments. The majority of commercial plans 
do not follow the Medicare payment model of using DRGs for paying healthcare providers. 
The logic in this present study of standardizing pricing is based on the Medicare regulatory 
regime for paying providers. Another explanation for the results having higher mean episode 
payments than those in previous studies could be related to the fact that all amounts of the 
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present study were adjusted to 2018 U.S. dollars. Previous studies were conducted in earlier 
study periods (see Table1) and economic factors, such as inflation, did not offset the change 
in payments to 2018 U.S. dollars.  
Furthermore, the literature suggested additional reasons for such differences in 
payments between private and public payers.[85] First, the market power of healthcare 
providers over private payers might be a reason for having higher payments than Medicare. 
The market power of Medicare could have enabled it to enforce tighter limits on healthcare 
providers’ payments. Another possible reason is the cost shift theory,[86] which implies that 
public payers reimburse healthcare providers less than their costs, leading healthcare 
providers to charge private payers well above costs to offset the losses from public payers. 
Given the differences of the data sources and the study populations, the similarity of the 
present study findings with those of previous studies suggested that wide variations existed in 
episode payments for both CABG surgeries and PCI procedures.  
When comparing commercial insurance payment amounts for CABG surgeries or PCI 
procedures from the present study’s results with the charge amounts from the literature and 
DSHS reports,[26, 52] a significant difference was observed. One study found the mean 
hospital charge for PCI procedures was $88,350.[52] In 2016, the mean hospital charge for 
PCI procedures in Texas was $126,823.[26] These charges were significantly higher than the 
mean index PCI procedure (i.e., hospital) payment of $28,316 that was found in this current 
study. In addition, there was a significant difference in amounts when comparing CABG 
surgery charges with commercial insurance payments. The mean hospital charge for CABG 
surgery in Texas was $234,560, which was substantially higher than the mean index CABG 
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payment of $48,886.[26] Thus, it is vital to distinguish between the two terms, charges and 
payments, when applying bundled payments. 
Finally, the primary findings of this study regarding both 90-day CABG episodes and 
90-day PCI episodes were established by aggregating episode payments and identifying 
payment components. Applying this approach allowed looking beyond CABG surgery and 
PCI procedure payments and gave us a comprehensive picture of post-discharge payments 
for commercially insured patients in Texas. 
Variation in Episode Payments 
The first two findings of this study were related to comparative statistics, which were 
performed to compare groups of episodes by patient characteristics. The results indicated 
variabilities in episode payments by certain patient factors, including patient regions, type of 
insurance, health plans, readmission stage, and comorbid conditions. 
First, the results showed sufficient evidence that the 90-day CABG episode payment 
for insured patients from at least one of the patient regions was different from the others. As 
a result, the null hypothesis of Aim 1A was rejected. Second, the study confirmed the 90-day 
PCI episode payment for commercially insured patients from at least one of the patient 
regions was different from the other Texas regions. Thus, the null hypothesis of Aim 1B was 
rejected. 
Unpredictably, the study’s results demonstrated that males and females did not have 
variability in the mean episode payments for either CABG surgeries or PCI procedures. 
While the literature indicated that females were associated with higher payments,[51, 61, 87] 
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there was also evidence in the literature that showed gender has no association with 
payments.[76]  
By comparing the findings of the present study using the proposed methodology to 
measure costs (i.e., 90-day episode payment) with the findings of a previous study that used a 
different method to measure costs (i.e., spending per member per year),[30] a consistency in 
the conclusions was observed. In other words, there is evidence of the existence of regional 
variations in healthcare costs across Texas. A previous report by the Institute of Medicine 
(IOM) suggested that decreasing regional variations would result in a reduction of healthcare 
expenditures.[88] William Edwards Deming, who is known as the father of quality 
management, said, “If I had to reduce my message for management to just a few words, I’d 
say it all had to do with reducing variation.”[89] By extension, efforts to reduce payment 
variation for CABG surgeries and PCI procedures might yield significant savings as well as 
improve efficiency.  
Predictors of Episode Payments 
Variation in CABG and PCI episode payments appeared to be influenced by multiple 
patient factors, including patient region, age, certain comorbidities, readmissions, lengths of 
stay, and insurance type (i.e., Medicare Advantage, commercial). The findings of the present 
study were in an agreement with the findings of previous studies that showed patient factors 
had an impact on CABG and PCI payments.[51, 52, 55, 59, 87] As the results demonstrated, based 
on the existence of variability in CABG and PCI payments by patient regions, the performed 
regression models have shown episode payments were lower for patients in the Austin region 
than those for the patients in the Houston region. One explanation could be that Austin had a 
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relatively lower readmission rate as compared to Houston or other Texas regions. Another 
possible reason for the geographic variation in payments for CABG surgeries and PCI 
procedures might be the regional differences in the supply of specialist physicians (e.g., 
number of cardiologists) and healthcare facilities (e.g., hospital beds), which may impact 
demand. Furthermore, it was noticed that episode payments were lower for patients in the 
Corpus Christi region than for patients in the Houston region. 
However, age was surprisingly found to be negatively associated with episode 
payments. Although age had a minimal overall association with payments in the present 
study, this finding was contrary to expectations and findings from other studies. No evidence 
in the literature was found suggesting that aging was negatively associated with episode 
payment for CABG surgeries or PCI procedures. In fact, several previous studies revealed a 
positive relationship between age and payments.[76, 87, 90] Another study showed that age had 
a minimal overall association with cost.[61] One explanation could be that Medicare 
Advantage patients, generally 65 years of age and older, had lower payments than 
commercial patients of the study population. Another possible reason is that the results of the 
present study could be attributed to myocardial infarction that was missed in younger patients 
(when compared to older patients) due to a lower index of suspicion. Therefore, a delay 
would have occurred in both the diagnosis and treatment of these patients. Such a delay could 
have resulted in a more complicated course of the disease and may have prolonged the care 
needed or health care utilizations in such patients, resulting in higher episode payments.  
Previous studies also showed that healthcare spending for Medicare Advantage 
patients was lower than those for commercially insured patients.[84, 91] The results of the 
96 
present study agreed with the findings of these studies, which showed that payments for 
Medicare Advantage patients were lower than those for commercially insured patients for 
both CABG and PCI episodes. This could suggest that healthcare utilizations of Medicare 
Advantage patients were lower than those of commercially insured patients. In other words, 
it is possible that healthcare providers rendered a substantially lower volume of healthcare 
services for Medicare Advantage insured patients than for commercially insured patients for 
both CABG and PCI procedures. This could be because the health plan (i.e., PPO, POS) 
might have had an impact on healthcare utilizations. This study found a strong collinearity 
between the type of insurance product (i.e., commercial, Medicare Advantage) and the health 
plan. It was more likely that a Medicare Advantage patient had a PPO health plan than a POS 
plan. On the other hand, it was more likely that a commercial insurance patient had a POS 
health plan than PPO health plan.  
The results of the present study demonstrated that certain comorbid conditions were 
associated with 90-day episode payments. These results were in line with the literature. The 
regression model showed that CABG episode payments were 10% higher for patients with 
peripheral vascular disease than for patients without this condition. However, the analysis 
demonstrated that patients with a history of cerebrovascular disease were associated with 
decreased 90-day CABG episode payments. No evidence in the literature was found 
suggesting this finding. One possible explanation is that CAD and cerebrovascular have 
similar pathophysiology. When patients with a history of cerebrovascular disease present 
with chest pain, the index of suspicion for CAD is very high. Thus, they have a higher chance 
of being diagnosed effectively and being treated earlier. For this reason, they would have a 
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lower chance of complications, which would also result in reduced healthcare utilization and 
payments. Furthermore, having high suspicion for CAD might lead to a more efficient 
utilization (i.e., more appropriate, specific, and preventative healthcare) of the healthcare 
services. A more efficient and effective healthcare delivery for these patients would 
eventually result in lowering their overall payments as well.  
For the PCI episode payments, the present study results showed that 90-day episode 
payments for patients with renal disease were 18 % higher than those for patients without 
renal disease. Additionally, the 90-day PCI episode payments for patients with diabetes with 
chronic complications were 15% higher than those for patients without. Patients with 
comorbidities that had a significant impact on costs could be considered under the high-
financial risk population when implementing bundled payments. Furthermore, strategies to 
improve diabetes control and to pay additional attention to those with comorbid renal disease 
conditions could effectively reduce 90-day PCI episode payments. 
Moreover, the present study showed that length of stay and readmission were 
significantly associated with higher payments for both CABG and PCI episodes. Being 
readmitted is a predominant predictor of CABG and PCI episode payments. Episode 
payments for readmitted CABG patients within a 30-day period, a 31-60-day period, and a 
61-90-day period were higher than those for non-readmitted patients. Likewise, episode 
payments for readmitted PCI patients within a 30-day period, a 31-60-day period, and a 61-
90-day period were higher than those for non-readmitted patients. By quantifying the costs of 
readmission, this study highlighted the potential opportunities to provide more efficient care 
and significantly improve the quality of care for CABG and PCI episodes across Texas 
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regions. In fact, the CMS has focused on readmission as one of its main national healthcare 
policies. For example, the Hospital Readmission Reduction Program, which is a Medicare 
value-based purchasing program, supports the goal of linking payments to the quality of care 
by seeking to penalize hospitals with high rates of readmissions for select conditions  
Because readmission stage was the predominant predictor of CABG and PCI episode 
payments, readmission rates across Texas were further analyzed. Among the regions, Austin 
had the lowest readmission rate for CABG episodes, and Corpus Christi had the lowest 
readmission rate for PCI episodes. The most common causes for 90-day readmissions for 
both CABG surgeries and PCI procedures were identified by detecting the DRGs used for 
readmissions. The most common DRG codes of readmissions for CABG episodes were 857, 
603, 291, 293, and 863. Three of these DRG codes were related to postoperative infections 
(i.e., 857, 603, 863), and two of these DRG codes were related to heart failure (i.e., 291, 
293). These causes of readmissions were in line with the literature.[51] The present study also 
showed a slightly higher readmission rate for CABG episode compared with another recent 
study on 90-day CABG episode payment variation for TRICARE beneficiaries (14% vs. 
13%).[31] Moreover, the most common DRG codes of readmissions for PCI episodes were 
247, 287, 291, 246, and 236. The findings showed that the DRG code 247 was the most 
common cause of readmission for PCI episodes, which was consistent with the literature.[64] 
However, the present study showed a slightly lower readmission rate for PCI episodes 
compared to another recent study on PCI episode payment variation (15.2% vs. 18.4%).[64]  
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Drivers of Variation in Episode Payments 
The third and fourth findings of this study demonstrated a considerable variation in 
payments across Texas. There was a wide variation in average 90-day episode payments 
across hospitals performing CABG surgery in Texas HRRs. The difference in average 90-day 
payments at hospitals in the highest and lowest payment quartiles was $45,121, representing 
73.9% higher payments at high-payment hospitals versus low-payment hospitals. Of the five 
payment components, the index procedure was found to be the key driver of CABG episode 
payment variation, contributing 48.6% of the total payment variation between high- and low-
payment hospitals. This finding was consistent with the reviewed studies that found the 
primary driver of payment variation in CABG episode was related to index procedure.[31, 51, 
55, 59] The second key driver of payment variation was readmission, contributing 19.8% of the 
total CABG episode payment variation between high- and low-payment hospitals. After this, 
professional services and post-acute care contributed to the total payment variation by 17.2% 
and 14.6%, respectively. The payment variation of professional services was driven in part 
by surgery payments, followed by anesthesia, and E&M. As a result, this finding has fulfilled 
Aim 2A of this research. Private payers and healthcare providers moving to the episode 
payment model for CABG surgeries should consider modeling their sources of variation by 
focusing on index hospitalizations.  
The final finding of this study demonstrated a wide variation in average 90-day 
episode payments across Texas hospitals performing PCI procedures. The difference in 
average 90-day payments to hospitals in the highest and lowest payment quartiles was 
$40,814, representing more than 100% higher payments at high-payment versus low-
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payment hospitals. Of the five payment components, the index procedure was the key driver 
of PCI episode payment variation, contributing 36.9% of the total payment variation between 
high- and low-payment hospitals. Although the present study demonstrated that the primary 
driver of the variation in PCI episode payments was related to the index procedure, the 
component with the highest difference rate between high- and low-payment hospitals was 
related to readmission (see Figure 10). This is in contrast to the study by Sukul et al. (2019) 
(see Table 1), which examined the 90-day PCI episode payment and found that the 
readmission payment was the primary driver of payment variation.[64] Finally, the present 
study determined that the second key driver of payment variation was post-acute care, 
contributing 35.8% of the total PCI episode payment variation between high and low-
payment hospitals. Post-acute care was driven in part by outpatient facility surgery as well as 
by ancillary services (i.e., services and supplies, durable medical equipment, administered 
drugs, and transportation services). With this final finding, this study has fulfilled Aim 2B of 
this research. Private payers and healthcare providers moving to the episode payment model 
for PCI procedures should understand the sources of payment variation by focusing on index 
procedure, outpatient facility surgeries, and ancillary services.  
Implications for Clinical Care, Quality Improvement, and Change in Practice 
While CABG surgeries and PCI procedures were not in episode (bundled) payment 
models for commercially insured patients, they may eventually become the first heart 
procedure to be included. In 2018, the CMS included these procedures as new voluntary 
episode payment models, which were qualified under the Medicare Quality Payment 
Program.[34, 39, 69] This initiative by the CMS could incentivize healthcare providers entering 
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episode payment models for CABG and PCI episodes. It could also motivate private payers 
to adapt the episode payment method to align provider incentives toward improving 
efficiency and healthcare quality. The findings of this research may contribute to the 
literature by giving insight into the variation of both CABG and PCI episode payments across 
commercially insured patient demographics and postoperative factors. Even though this 
study did not determine how much savings could be achieved by implementing CABG and 
PCI episode payments, it determined the type of services needed further investigation. 
The 90-day episode payments for CABG surgeries and PCI procedures across Texas 
appeared influenced by readmissions. A previous study showed a considerable proportion of 
readmissions after PCI procedures could have been prevented.[92] Thus, this research also 
highlighted opportunities for improvement and cost reductions. Because readmission is a 
much more prominent factor in the 90-day episode payments, an excellent target for cost 
reduction would to reduce readmissions. Strategies to contain the CABG and PCI episode 
payments may need to differ depending on the main causes of readmission as well as on the 
performance of hospitals with high readmission rates. For example, if linking payment to 
healthcare performance within the episode of care helps reduce readmissions, which would 
subsequently reduce payment, then this practice should be encouraged from a policy 
perspective. Transferring some of the financial risk to healthcare providers might be helpful. 
For example, holding healthcare providers finically accountable for high readmissions might 
be more appropriate for reducing readmissions and, subsequently, episode payments.  
Furthermore, healthcare policies, such as those that are relevant to improving the 
transparency of healthcare performance and payment data available to patients, might help 
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reduce payment variation. For example, when information about quality and payment, 
including out-of-pocket expenses, are offered to patients, it could be used to incentivize 
patients that need CABG or PCI procedures to request surgeries from high-quality healthcare 
providers such as those hospitals with lower readmission rates. As a result, hospitals with 
high readmissions could focus on improving their performance and reducing their 
readmissions. Therefore, payments could be reduced.  
Efforts to improve care for patients with certain comorbidities (e.g., renal disease, 
diabetes with chronic complications, and peripheral vascular disease) would yield significant 
savings. Insurers might stratify patients into categories based on their comorbid conditions 
and severity of illness and then adjust episode payments based those that cost more. In 
addition, clinical practice guidelines could be developed to manage certain comorbidities of 
patients undergoing CABG surgeries or PCI procedures, such as conducting 
multidisciplinary interactive sessions. The clinical care practices of 90-day episodes for 
CABG surgeries and PCI procedures appeared to be lower in utilization in the Austin and 
Corpus Christi regions than the other Texas regions. Their practices could be inspected and 
shared with the healthcare settings in the Houston and in other high-cost regions in support of 
an in-depth investigation and quality improvement. 
Payment variations for CABG episodes and PCI episodes differ in terms of 
contribution to 90-day payment variation between high- and low-cost hospitals. Across 
Texas, high cost hospitals for CABG episodes were not necessarily high cost hospitals for 
PCI episodes. Furthermore, high cost regions for CABG were not necessarily high cost 
regions for PCI. These results suggested that policy makers should consider the 
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characteristics of hospitals as well as regions when developing policies for healthcare 
efficiency. 
The present study’s findings also provided insight about the distribution of 90-day 
episode payment across the five payment components for CABG surgeries and PCI 
procedures. Index payments not only comprised the largest proportion of CABG and PCI 
episode payments, but they also represented the key source of variations. The results of this 
study demonstrated that index procedure payment was the primary driver of payment 
variations. Thus, healthcare providers entering episode-based payment models for CABG and 
PCI should consider the need to understand the key drivers of payment variation in CABG 
and PCI episodes when developing initiatives to reduce related spending. Finally, this study 
might contribute to defining the essential targets of payment reform and improving efficiency 
in CABG and PCI episode.  
Limitations 
Although this study provided an understanding of costs for CABG surgeries and PCI 
procedures for commercially insured patients in Texas, it was not without limitations. The 
claims data were designed to justify payment, but they lacked the rich clinical details found 
in patient medical charts. As a result, detailed clinical variables that could have affected 
payments were not examined. This data, however, did include some valuable clinical 
information (i.e., diagnosis and procedure codes) that was used to track comorbid conditions. 
In addition, the present study also did not account for planned and unplanned readmissions. 
This is similar to the limitations of another recent study in which bundled payment models 
also did not exclude staged or planned PCIs from episodes of care.[64]  
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Furthermore, the claims data used for this research did not allow for an examination 
of the effectiveness of the two procedures (i.e., CABG and PCI) or for a clinical comparison 
between them. They had limited clinical details and outcome measures. For this reason, no 
inference could be made about to which extent undergoing CABG surgeries or PCI 
procedures reflects high- or low-effectiveness. However, the aim of the present study was not 
to determine the effectiveness of the two procedures (i.e., CABG and PCI). The two primary 
aims of this research were to examine variation in CABG and PCI episode payments across 
Texas and to examine the payment components that drive the variability. 
Moreover, the datasets used for this study did not include information about the 
deaths of patients. In response to this, episodes with fewer than two claims after the 
discharge date were identified to ensure none of the study population died during index 
hospitalization. There is, however, a possibility that some of the patients included in the 
study died during the 90-day post-discharge.   
 Another limitation was that the claims data for this study did not include important 
provider characteristics because of the payer-provider contractual agreements. For example, 
the datasets did not include hospital zip codes, which could have affected the basis for 
determining the exact geographic pattern of healthcare utilization. However, according to the 
DAHC, most patients in the U.S. are generally admitted to hospitals close to where they 
live.[29]  
 Finally, the study was limited to a particular group of privately insured patients in 
Texas, which affects its generalizability to other populations outside of Texas. Despite these 
limitations, patient demographics and operative predictors were considered while 
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determining CABG and PCI episode payments and identifying the drivers of payment 
variation across Texas. Thus, the claims data this study used were unique in that they 
provided comprehensive payment information for a large and broadly representative 
commercially insured population in Texas. As a result, this study might be generalizable to 
other commercially insured populations in Texas.  
CONCLUSIONS 
This study simulated potential episode payments in patients who underwent CABG 
surgeries and PCI procedures in Texas. It provided insight into CABG episode payment as 
well as insight into the PCI episode payments across Texas. In addition, the present study 
filled a knowledge gap by exploring the variation in CABG and PCI payments among 
various factors of commercially insured patients in Texas. The findings indicated that both 
CABG and PCI episode payments vary widely with the patients’ regions, ages, and 
comorbidities. Payments also varied with other patient clinical factors, including length of 
stay and readmission, as well as whether patients were using commercial insurance or 
Medicare Advantage. Readmission was the most influential independent predictor of higher 
payments for patients undergoing CABG surgeries and PCI procedures. These results have 
contributed to a better understanding of the current variation of CABG and PCI payments 
across Texas as well as to the present association of patient characteristics to total episode 
payments. In other words, it was found that there were significant variations in episode 
payments involved with patient characteristics. 
This study reported that the variations in CABG and PCI episode payments between 
low- and high-payment hospitals in Texas were mainly attributable to differences in index 
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procedure payments. The findings of this study in the payment variation drivers may 
contribute to an understanding of the current distribution of payments across both CABG and 
PCI episodes. These drivers should be considered when developing initiatives to reduce 
healthcare spending. They could also serve to inform policymakers, payers, and healthcare 
providers about the implementation of bundled payment initiatives. The variation suggested 
that within a bundled payment model, there may be considerable cost savings for the 
healthcare system. These cost savings lie mainly within quality improvement programs to 
ensure best practices and decrease readmissions.  
This study could be replicated among other private payers in other states to allow for 
conclusions that are more generalizable and robust. The findings of this study suggested the 
need for in-depth research for hospital- and regional-level factors associated with 90-day 
CABG and PCI episode payments. Further studies could provide valuable insights by 
exploring the role of hospital and regional characteristics in predicting episode payments. 
Finally, the findings of the present study might prove useful for a further understanding of 
CABG and PCI episode payments in commercially insured patients in Texas, and they also 
might encourage further studies to examine the comparative effectiveness of CABG surgeries 
versus PCI procedures in this population. 
107 
APPENDICES 
Appendix A: Codes Used in the Data Extraction of the Study Population for CABG Episodes  
Code Type Code Description 
MS-DRG 231 Coronary Bypass with PTCA with MCC  
232 Coronary Bypass with PTCA without MCC 
233 Coronary Bypass with Cardiac Cath with MCC 
234 Coronary Bypass with Cardiac Cath without MCC 
235 Coronary Bypass without Cardiac Cath with MCC 
236 Coronary Bypass without Cardiac Cath without MCC 
HCPCS S2205 Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or 
mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single 
coronary arterial graft (S2205) 
S2206 Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or 
mini-sternotomy surgery, performed under direct vision; using arterial graft(s), two coronary 
arterial grafts (S2206) 
S2207 Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or 
mini-sternotomy surgery, performed under direct vision; using venous graft only, single 
coronary venous graft (S2207) 
S2208 Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or 
mini-sternotomy surgery, performed under direct vision; using single arterial and venous 
graft(s), single venous graft (S2208) 
S2209 Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or 
mini-sternotomy surgery, performed under direct vision; using two arterial grafts and single 
venous graft (S2209) 
CPT 33510 Under Venous Grafting Only for Coronary Artery Bypass 
33511 Coronary artery bypass, vein only 
33512 Coronary artery bypass, vein only 
33513 Venous Grafting Only for Coronary Artery Bypass. 
33514 Venous Grafting Only for Coronary Artery Bypass. 
33516 Venous Grafting Only for Coronary Artery Bypass 
33517 Combined Arterial-Venous Grafting for Coronary Bypass 
33518 Combined Arterial-Venous Grafting for Coronary Bypass 
33519 Combined Arterial-Venous Grafting for Coronary Bypass 
33521 Combined Arterial-Venous Grafting for Coronary Bypass 
33522 Combined Arterial-Venous Grafting for Coronary Bypass. 
33523 Combined Arterial-Venous Grafting for Coronary Bypass 
33533 Arterial Grafting for Coronary Artery Bypass. 
33534 Arterial Grafting for Coronary Artery Bypass 
33535 Arterial Grafting for Coronary Artery Bypass 
33536 Arterial Grafting for Coronary Artery Bypass. 
ICD 10 210093 Bypass Coronary Artery, One Site to Coronary Artery with 
210098 Bypass Coronary Artery, One Site to Right Internal Mammary 
210099 Bypass Coronary Artery, One Site to Left Internal Mammary 
211093 Bypass Coronary Artery, Two Sites to Coronary Artery with 
211098 Bypass Coronary Artery, Two Sites to Right Internal Mammary 
211099 Bypass Coronary Artery, Two Sites to Left Internal Mammary 
212093 Bypass Coronary Artery, Three Sites to Coronary Artery with 
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212098 Bypass Coronary Artery, Three Sites to Right Internal Mammary 
212099 Bypass Coronary Artery, Three Sites to Left Internal Mammary 
213093 Bypass Coronary Artery, Four or More Sites to Coronary Artery 
213098 Bypass Coronary Artery, Four or More Sites to Right Internal Mammary with Autologous 
Venous Tissue, Open Approach 
213099 Bypass Coronary Artery, Four or More Sites to Left Internal Mammary with Autologous 
Venous Tissue, Open Approach 
021009C Bypass Coronary Artery, One Site to Thoracic Artery with 
021009F Bypass Coronary Artery, One Site to Abdominal Artery with 
021009W Bypass Coronary Artery, One Site to Aorta with Autologous 
02100A3 Bypass Coronary Artery, One Site to Coronary Artery with 
02100A8 Bypass Coronary Artery, One Site to Right Internal Mammary 
02100A9 Bypass Coronary Artery, One Site to Left Internal Mammary 
02100AC Bypass Coronary Artery, One Site to Thoracic Artery with 
02100AF Bypass Coronary Artery, One Site to Abdominal Artery with 
02100AW Bypass Coronary Artery, One Site to Aorta with Autologous 
02100J3 Bypass Coronary Artery, One Site to Coronary Artery with 
02100J8 Bypass Coronary Artery, One Site to Right Internal Mammary 
02100J9 Bypass Coronary Artery, One Site to Left Internal Mammary with 
02100JC Bypass Coronary Artery, One Site to Thoracic Artery with 
02100JF Bypass Coronary Artery, One Site to Abdominal Artery with 
02100JW Bypass Coronary Artery, One Site to Aorta with Synthetic 
02100K3 Bypass Coronary Artery, One Site to Coronary Artery with 
02100K8 Bypass Coronary Artery, One Site to Right Internal Mammary 
02100K9 Bypass Coronary Artery, One Site to Left Internal Mammary 
02100KC Bypass Coronary Artery, One Site to Thoracic Artery with 
02100KF Bypass Coronary Artery, One Site to Abdominal Artery with 
02100KW Bypass Coronary Artery, One Site to Aorta with Nonautologous 
02100Z3 Bypass Coronary Artery, One Site to Coronary Artery, Open 
02100Z8 Bypass Coronary Artery, One Site to Right Internal Mammary, 
02100Z9 Bypass Coronary Artery, One Site to Left Internal Mammary, 
02100ZC Bypass Coronary Artery, One Site to Thoracic Artery, Open 
02100ZF Bypass Coronary Artery, One Site to Abdominal Artery, Open 
021109C Bypass Coronary Artery, Two Sites to Thoracic Artery with 
021109F Bypass Coronary Artery, Two Sites to Abdominal Artery with 
021109W Bypass Coronary Artery, Two Sites to Aorta with Autologous 
02110A3 Bypass Coronary Artery, Two Sites to Coronary Artery with 
02110A8 Bypass Coronary Artery, Two Sites to Right Internal Mammary 
02110A9 Bypass Coronary Artery, Two Sites to Left Internal Mammary 
02110AC Bypass Coronary Artery, Two Sites to Thoracic Artery with 
02110AF Bypass Coronary Artery, Two Sites to Abdominal Artery with 
02110AW Bypass Coronary Artery, Two Sites to Aorta with Autologous 
02110J3 Bypass Coronary Artery, Two Sites to Coronary Artery with 
02110J8 Bypass Coronary Artery, Two Sites to Right Internal Mammary 
02110J9 Bypass Coronary Artery, Two Sites to Left Internal Mammary 
02110JC Bypass Coronary Artery, Two Sites to Thoracic Artery with 
02110JF Bypass Coronary Artery, Two Sites to Abdominal Artery with 
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02110JW Bypass Coronary Artery, Two Sites to Aorta with Synthetic 
02110K3 Bypass Coronary Artery, Two Sites to Coronary Artery with 
02110K8 Bypass Coronary Artery, Two Sites to Right Internal Mammary 
02110K9 Bypass Coronary Artery, Two Sites to Left Internal Mammary 
02110KC Bypass Coronary Artery, Two Sites to Thoracic Artery with 
02110KF Bypass Coronary Artery, Two Sites to Abdominal Artery with 
02110KW Bypass Coronary Artery, Two Sites to Aorta with 
02110Z3 Bypass Coronary Artery, Two Sites to Coronary Artery, Open 
02110Z8 Bypass Coronary Artery, Two Sites to Right Internal Mammary, 
02110Z9 Bypass Coronary Artery, Two Sites to Left Internal Mammary, 
02110ZC Bypass Coronary Artery, Two Sites to Thoracic Artery, Open 
02110ZF Bypass Coronary Artery, Two Sites to Abdominal Artery, Open 
021209C Bypass Coronary Artery, Three Sites to Thoracic Artery with 
021209F Bypass Coronary Artery, Three Sites to Abdominal Artery with 
021209W Bypass Coronary Artery, Three Sites to Aorta with Autologous 
02120A3 Bypass Coronary Artery, Three Sites to Coronary Artery with 
02120A8 Bypass Coronary Artery, Three Sites to Right Internal Mammary 
02120A9 Bypass Coronary Artery, Three Sites to Left Internal Mammary 
02120AC Bypass Coronary Artery, Three Sites to Thoracic Artery with 
02120AF Bypass Coronary Artery, Three Sites to Abdominal Artery with 
02120AW Bypass Coronary Artery, Three Sites to Aorta with Autologous 
02120J3 Bypass Coronary Artery, Three Sites to Coronary Artery with 
02120J8 Bypass Coronary Artery, Three Sites to Right Internal Mammary 
02120J9 Bypass Coronary Artery, Three Sites to Left Internal Mammary 
02120JC Bypass Coronary Artery, Three Sites to Thoracic Artery with 
02120JF Bypass Coronary Artery, Three Sites to Abdominal Artery with 
02120JW Bypass Coronary Artery, Three Sites to Aorta with Synthetic 
02120K3 Bypass Coronary Artery, Three Sites to Coronary Artery with 
02120K8 Bypass Coronary Artery, Three Sites to Right Internal Mammary 
02120K9 Bypass Coronary Artery, Three Sites to Left Internal Mammary 
02120KC Bypass Coronary Artery, Three Sites to Thoracic Artery with 
02120KF Bypass Coronary Artery, Three Sites to Abdominal Artery with 
02120KW Bypass Coronary Artery, Three Sites to Aorta with 
02120Z3 Bypass Coronary Artery, Three Sites to Coronary Artery, Open 
02120Z8 Bypass Coronary Artery, Three Sites to Right Internal Mammary, 
02120Z9 Bypass Coronary Artery, Three Sites to Left Internal Mammary, 
02120ZC Bypass Coronary Artery, Three Sites to Thoracic Artery, Open 
02120ZF Bypass Coronary Artery, Three Sites to Abdominal Artery, Open 
021309C Bypass Coronary Artery, Four or More Sites to Thoracic Artery 
021309F Bypass Coronary Artery, Four or More Sites to Abdominal Artery with Autologous Venous 
Tissue, Open Approach 
021309W Bypass Coronary Artery, Four or More Sites to Aorta with 
02130A3 Bypass Coronary Artery, Four or More Sites to Coronary Artery 
02130A8 Bypass Coronary Artery, Four or More Sites to Right Internal Mammary with Autologous 
Arterial Tissue, Open Approach 
02130A9 Bypass Coronary Artery, Four or More Sites to Left Internal Mammary with Autologous 
Arterial Tissue, Open Approach 
02130AC Bypass Coronary Artery, Four or More Sites to Thoracic Artery 
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02130AF Bypass Coronary Artery, Four or More Sites to Abdominal Artery with Autologous Arterial 
Tissue, Open Approach 
02130AW Bypass Coronary Artery, Four or More Sites to Aorta with Autologous Arterial Tissue, Open 
Approach 
02130J3 Bypass Coronary Artery, Four or More Sites to Coronary Artery 
02130J8 Bypass Coronary Artery, Four or More Sites to Right Internal 
02130J9 Bypass Coronary Artery, Four or More Sites to Left Internal 
02130JC Bypass Coronary Artery, Four or More Sites to Thoracic Artery 
02130JF Bypass Coronary Artery, Four or More Sites to Abdominal Artery 
02130JW Bypass Coronary Artery, Four or More Sites to Aorta with 
02130K3 Bypass Coronary Artery, Four or More Sites to Coronary Artery 
02130K8 Bypass Coronary Artery, Four or More Sites to Right Internal Mammary with Nonautologous 
Tissue Substitute, Open Approach 
02130K9 Bypass Coronary Artery, Four or More Sites to Left Internal Mammary with Nonautologous 
Tissue Substitute, Open Approach 
02130KC Bypass Coronary Artery, Four or More Sites to Thoracic Artery 
02130KF Bypass Coronary Artery, Four or More Sites to Abdominal Artery with Nonautologous 
Tissue Substitute, Open Approach 
02130KW Bypass Coronary Artery, Four or More Sites to Aorta with 
02130Z3 Bypass Coronary Artery, Four or More Sites to Coronary Artery, 
02130Z8 Bypass Coronary Artery, Four or More Sites to Right Internal 
02130Z9 Bypass Coronary Artery, Four or More Sites to Left Internal 
02130ZC Bypass Coronary Artery, Four or More Sites to Thoracic Artery, 
02130ZF Bypass Coronary Artery, Four or More Sites to Abdominal  
ICD-9 36.1 Aortocoronary bypass NOS 
36.11 Aortocor bypas-1 cor art 
36.12 Aortocor bypas-2 cor art 
36.13 Aortocor bypas-3 cor art 
36.14 Aortcor bypas-4+ cor art 
36.15 1 int mam-cor art bypass 
36.16 2 int mam-cor art bypass 
36.17 Abd-coron artery bypass 
36.19 Hrt revas byps anas NEC 
36.2 Arterial implant revasc 
Note: CPT-4, Current Procedural Terminology 4; ICD-10-CM, International Classification of Diseases, 10th Revision; 
ICD-9, International Classification of Diseases, 9th Revision; MS-DRG, Medicare Severity Diagnosis Related Groups; 








MS-DRG  246 Percutaneous Cardiovascular Procedures with Drug-Eluting Stent with MCC 
or 4+ Arteries or Stents  
 247 Percutaneous Cardiovascular Procedures with Drug-Eluting Stent without 
MCC 
 248 Percutaneous Cardiovascular Procedures with Non-Drug-Eluting Stent with 
MCC or 4+ Arteries or Stents 
 249 Percutaneous Cardiovascular Procedures with Non-Drug-Eluting Stent 
without MCC 
 250 Percutaneous Cardiovascular Procedures without Coronary Artery Stent with 
MCC  
 251 Percutaneous Cardiovascular Procedures without Coronary Artery Stent 
without MCC 
 273 Percutaneous Intracardiac Procedures with MCC 
 274 Percutaneous Intracardiac Procedures without MCC 
HCPCS 
  
92920 Percutaneous transluminal coronary angioplasty; single major coronary 
artery or branch 
C9600 Percutaneous transcatheter placement of drug eluting intracoronary stent(s), 
with coronary angioplasty when performed; single major coronary artery or 
branch 
C9604  Percutaneous transluminal revascularization of or through coronary artery 
bypass graft (internal mammary, free arterial, venous), any combination of 
drug 
92937 Percutaneous transluminal revascularization of or through coronary artery 
bypass graft (internal mammary, free arterial, venous), any combination of 
intracoronary stent, atherectomy and angioplasty, including distal protection 
when performed; single vessel 
92924  Percutaneous transluminal coronary atherectomy, with coronary angioplasty 
when performed; single major coronary artery or branch 
92928  Percutaneous transcatheter placement of intracoronary stent(s), with 
coronary angioplasty when performed; single major coronary artery or 
branch 
92943  Percutaneous transluminal revascularization of chronic total occlusion, 
coronary artery, coronary artery branch, or coronary artery bypass graft, any 
combination of intracoronary stent, atherectomy and angioplasty; single 
vessel 
C9606  Percutaneous transluminal revascularization of acute total/subtotal occlusion 
during acute myocardial infarction, coronary artery or coronary artery bypass 
graft, any combination of drug 
92933 Percutaneous transluminal coronary atherectomy, with intracoronary stent, 
with coronary angioplasty when performed; single major coronary artery or 
branch 
C9607 Percutaneous transluminal revascularization of chronic total occlusion, 
coronary artery, coronary artery branch, or coronary artery bypass graft, any 
combination of drug 
C9602  Percutaneous transluminal coronary atherectomy, with drug eluting 
intracoronary stent, with coronary angioplasty when performed; single major 
coronary artery or branch 
CPT 92941 Coronary Therapeutic Services and Procedures 
92943 Coronary Therapeutic Services and Procedures 
92980 Coronary Therapeutic Services and Procedures 
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92982 Coronary Therapeutic Services and Procedures 
92995 Coronary Therapeutic Services and Procedures 
ICD-10 270346  Dilation of Coronary Artery, One Site, Bifurcation, with Drug‐ 
270446  Dilation of Coronary Artery, One Site, Bifurcation, with Drug‐ eluting 
Intraluminal Device, Percutaneous Endoscopic Approach 
271346  Dilation of Coronary Artery, Two Sites, Bifurcation, with Drug‐ 
271446  Dilation of Coronary Artery, Two Sites, Bifurcation, with Drug‐ eluting 
Intraluminal Device, Percutaneous Endoscopic Approach 
272346  Dilation of Coronary Artery, Three Sites, Bifurcation, with Drug‐ 
272446  Dilation of Coronary Artery, Three Sites, Bifurcation, with Drug‐ eluting 
Intraluminal Device, Percutaneous Endoscopic Approach 
273346  Dilation of Coronary Artery, Four or More Sites, Bifurcation, with Drug‐
eluting Intraluminal Device, Percutaneous Approach 
273446  Dilation of Coronary Artery, Four or More Sites, Bifurcation, with Drug‐
eluting Intraluminal Device, Percutaneous Endoscopic Approach 
027034Z  Dilation of Coronary Artery, One Site with Drug‐eluting 
02703D6  Dilation of Coronary Artery, One Site, Bifurcation, with 
02703DZ  Dilation of Coronary Artery, One Site with Intraluminal Device, 
02703T6  Dilation of Coronary Artery, One Site, Bifurcation, with 
02703TZ  Dilation of Coronary Artery, One Site with Radioactive 
02703Z6  Dilation of Coronary Artery, One Site, Bifurcation, Percutaneous 
02703ZZ  Dilation of Coronary Artery, One Site, Percutaneous Approach 
027044Z  Dilation of Coronary Artery, One Site with Drug‐eluting 
02704D6  Dilation of Coronary Artery, One Site, Bifurcation, with 
02704DZ  Dilation of Coronary Artery, One Site with Intraluminal Device, 
02704T6  Dilation of Coronary Artery, One Site, Bifurcation, with Radioactive 
Intraluminal Device, Percutaneous Endoscopic Approach 
02704TZ  Dilation of Coronary Artery, One Site with Radioactive 
02704Z6  Dilation of Coronary Artery, One Site, Bifurcation, Percutaneous 
02704ZZ  Dilation of Coronary Artery, One Site, Percutaneous Endoscopic 
027134Z  Dilation of Coronary Artery, Two Sites with Drug‐eluting 
02713D6  Dilation of Coronary Artery, Two Sites, Bifurcation, with 
02713DZ  Dilation of Coronary Artery, Two Sites with Intraluminal Device, 
02713T6  Dilation of Coronary Artery, Two Sites, Bifurcation, with 
02713TZ  Dilation of Coronary Artery, Two Sites with Radioactive 
02713Z6  Dilation of Coronary Artery, Two Sites, Bifurcation, 
02713ZZ  Dilation of Coronary Artery, Two Sites, Percutaneous Approach 
027144Z  Dilation of Coronary Artery, Two Sites with Drug‐eluting 
02714D6  Dilation of Coronary Artery, Two Sites, Bifurcation, with 
02714DZ  Dilation of Coronary Artery, Two Sites with Intraluminal Device, 
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02714T6  Dilation of Coronary Artery, Two Sites, Bifurcation, with Radioactive 
Intraluminal Device, Percutaneous Endoscopic Approach 
02714TZ  Dilation of Coronary Artery, Two Sites with Radioactive 
02714Z6  Dilation of Coronary Artery, Two Sites, Bifurcation, 
02714ZZ  Dilation of Coronary Artery, Two Sites, Percutaneous 
027234Z  Dilation of Coronary Artery, Three Sites with Drug‐eluting 
02723D6  Dilation of Coronary Artery, Three Sites, Bifurcation, with 
02723DZ  Dilation of Coronary Artery, Three Sites with Intraluminal 
02723T6  Dilation of Coronary Artery, Three Sites, Bifurcation, with 
02723TZ  Dilation of Coronary Artery, Three Sites with Radioactive 
02723Z6  Dilation of Coronary Artery, Three Sites, Bifurcation, 
02723ZZ  Dilation of Coronary Artery, Three Sites, Percutaneous 
027244Z  Dilation of Coronary Artery, Three Sites with Drug‐eluting 
02724D6  Dilation of Coronary Artery, Three Sites, Bifurcation, with 
02724DZ  Dilation of Coronary Artery, Three Sites with Intraluminal 
02724T6  Dilation of Coronary Artery, Three Sites, Bifurcation, with Radioactive 
Intraluminal Device, Percutaneous Endoscopic Approach 
02724TZ  Dilation of Coronary Artery, Three Sites with Radioactive Intraluminal 
Device, Percutaneous Endoscopic Approach 
02724Z6  Dilation of Coronary Artery, Three Sites, Bifurcation, 
02724ZZ  Dilation of Coronary Artery, Three Sites, Percutaneous 
027334Z  Dilation of Coronary Artery, Four or More Sites with Drug‐ 
02733D6  Dilation of Coronary Artery, Four or More Sites, Bifurcation, 
02733DZ  Dilation of Coronary Artery, Four or More Sites with 
02733T6  Dilation of Coronary Artery, Four or More Sites, Bifurcation, with 
Radioactive Intraluminal Device, Percutaneous Approach 
02733TZ  Dilation of Coronary Artery, Four or More Sites with Radioactive 
02733Z6  Dilation of Coronary Artery, Four or More Sites, Bifurcation, 
02733ZZ  Dilation of Coronary Artery, Four or More Sites, Percutaneous 
027344Z  Dilation of Coronary Artery, Four or More Sites with Drug‐ eluting 
Intraluminal Device, Percutaneous Endoscopic Approach 
02734D6  Dilation of Coronary Artery, Four or More Sites, Bifurcation, with 
Intraluminal Device, Percutaneous Endoscopic Approach 
02734DZ  Dilation of Coronary Artery, Four or More Sites with 
02734T6  Dilation of Coronary Artery, Four or More Sites, Bifurcation, with 
Radioactive Intraluminal Device, Percutaneous Endoscopic Approach 
02734TZ  Dilation of Coronary Artery, Four or More Sites with Radioactive 
Intraluminal Device, Percutaneous Endoscopic Approach 
02734Z6  Dilation of Coronary Artery, Four or More Sites, Bifurcation, 
02734ZZ  Dilation of Coronary Artery, Four or More Sites, Percutaneous 
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ICD-9  0.66 PTCA 
36.06 Ins nondrug elut cor st 
36.07 Ins drug‐elut coronry st 
Note: CPT 4, Current Procedural Terminology 4; ICD-10-CM, International Classification of 
Diseases, 10th Revision; ICD-9, International Classification of Diseases, 9th Revision; MS-DRG, 
Medicare Severity Diagnosis Related Groups; HCPCS, Healthcare Common Procedure Coding System 
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Appendix C: Codes to Identify the Presence of Each Condition in the Adapted Charlson 
Comorbidity Index  
Score 
Weights* 
Description Code (ICD-9-CM) ICD-10 
1 Myocardial infarction 410.X, 412.X I21.X, I22.X, I25.2 
1 Congestive heart failure 398.91, 402.01, 402.11, 402.91, 
404.01, 404.03, 404.11, 404.13, 
404.91, 404.93, 425.4-425.9, 
428.X  
I09.9, I11.0, I13.0, I13.2, 
I25.5, I42.0, I42.5-I42.9, 
I43.X, I50.X, P29.0 
1 Peripheral vascular disease 093.0, 437.3, 440.X, 441.X, 
443.1-443.9, 447.1, 557.1, 557.9, 
V43.4  
I70.X, I71.X, I73.1, I73.8, 
I73.9, I77.1, I79.0, I79.2, 
K55.1, K55.8, K55.9, Z95.8, 
Z95.9 
1 Cerebrovascular disease 362.34, 430.X-438.X  G45.X, G46.X, H34.0, I60.X-
I69.X 
2 Dementia  290.X, 294.1, 331.2  F00.X-F03.X, F05.1, G30.X, 
G31.1 
1 Chronic pulmonary disease 416.8, 416.9, 490.X-505.X, 
506.4, 508.1, 508.8  
I27.8, I27.9, J40.X-J47.X, 
J60.X-J67.X, J68.4, J70.1, 
J70.3 
1 Rheumatologic disease 446.5, 710.0-710.4, 714.0-714.2, 
714.8, 725.X  
M05.X, M06.X, M31.5, 
M32.X-M34.X, M35.1, 
M35.3, M36.0 
1 Peptic ulcer disease 531.X-534.X  K25.X-K28.X 
1* Mild liver disease 070.22, 070.23, 070.32, 070.33, 
070.44, 070.54, 070.6, 070.9, 
570.X, 571.X, 573.3, 573.4, 
573.8, 573.9, V42.7  
B18.X, K70.0-K70.3, K70.9, 
K71.3-K71.5, K71.7, K73.X, 
K74.X, K76.0, K76.2-K76.4, 
K76.8, K76.9, Z94.4 
1** Diabetes without chronic 
complications 
250.0-250.3, 250.8, 250.9  
  
E10.0, E10.L, E10.6, E10.8, 
E10.9, E11.0, E11.1, E11.6, 
E11.8, E11.9, E12.0, E12.1, 
E12.6, E12.8, E12.9, E13.0, 
E13.1, E13.6, E13.8, E13.9, 
E14.0, E14.1, E14.6, E14.8, 
E14.9 
2 Diabetes with chronic 
complications 
250.4-250.7 E10.2-E10.5, E10.7, E11.2-
E11.5, E11.7, E12.2-E12.5, 
E12.7, E13.2-E13.5, E13.7, 
E14.2-E14.5, E14.7 
1 Hemiplegia or paraplegia 334.1, 342.X, 343.X, 344.0-
344.6, 344.9  
G04.1, G11.4, G80.1, G80.2, 
G81.X, G82.X, G83.0-G83.4, 
G83.9 
2 Renal disease 403.01, 403.11, 403.91, 404.02, 
404.03, 404.12, 404.13, 404.92, 
404.93, 582.X, 583.0-583.7, 
585.X, 586.X, 588.0, V42.0, 
V45.1, V56.X  
I12.0, I13.1, N03.2-N03.7, 
N05.2-N05.7, N18.X, N19.X, 
N25.0, Z49.0-Z49.2, Z94.0, 
Z99.2 
2 Any malignancy, including 
lymphoma and leukemia, except 
malignant neoplasm of skin 
140.X-172.X, 174.X-195.8, 




C85.X, C88.X, C90.X-C97.X 
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3 Moderate or severe liver disease 456.0-456.2, 572.2-572.8  I85.0, I85.9, I86.4, I98.2, 
K70.4, K71.1, K72.1, K72.9, 
K76.5, K76.6, K76.7 
6 Metastatic solid tumor 196.X-199.X  C77.X-C80.X 
6 AIDS/HIV 042.X-044.X  B20.X-B22.X, B24.X 
Note: Adapted from the data dictionary of Optum claims data.[72, 74, 75] 
* If a patient found to have diabetes with chronic complication, the weight of diabetes without chronic complication was 
changed to 0 
** If a patient found to have moderate or severe liver disease, the weight of mild liver disease was changed 0 
(i.e., the minimum possible CCI score was 0 while the maximum possible CCI score was 31) 
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Appendix D: Personal Consumption Expenditures: Health (Chain-type price index)  
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Appendix E: Variable Descriptions of the Extracted Claims Data 
VARIABLE DESCRIPTION TYPE 
PATID An encrypted, system-generated number that identifies an individual across multiple 
groups/policies. This identifier is not derived from information about the individual and is 
compliant with HIPAA §164.514c. 
Num 
BUS Identifies the type of business the product is intended to service. Char 
ELIGEFF The date this member coverage row of information is effective. Num 
ELIGEND The date this member coverage row of information ended (or will end). Num 
GDR_CD A code identifying the sex of the member M=male, F=female, U=unknown Char 
PRODUCT The code commonly used by the health care industry to identify the product. Char 
YRDOB The member's year of birth, capped at 90 years. Num 
ZIPCODE_5 Collapsed 5-digit postal zip code developed from statistical analysis of US Census data. 5-
digit zip codes are either presented alone, collapsed into other 5-digit zip codes, or not 
reported depending on the statistical analysis results. 
Char 
CLMID Encrypted Claim ID. A provider can bill multiple revenue codes for services rendered on 
one claim. Each revenue code will generate a claim line. Providers typically submit 
separate claim for each visit they have with a patient. 
Char 
CLMSEQ Number assigned in the source system to the service within the claim. This field is used to 
distinguish between the detail records for a claim. Use with CLMID 
Char 
DRG The Diagnosis Related Group (DRG) Code assigned by the source system. A DRG 
classifies patients by diagnostic or surgical procedure into major diagnostic categories for 
the purpose of determining payment of hospitalization charges. Effective 10/1/2007, the 
Centers for Medicare and Medicaid Services (CMS) introduced the MS-DRG code set and 
retired the CMS-DRG set. The new code set refined the DRGs based on the presence of 
complications or co-morbidities. One effect of this change is that the MS-DRG descriptions 
are completely different from previous descriptions. The DRG code table contains 
historical CMS-DRGs as well as MS-DRG codes.  
Char 
FST_DT The beginning date for the service, event, or confinement being billed by the provider. Num 
ICD_FLAG ICD Version Code will distinguish between ICD-9 and ICD-10 codes.  Char 
LST_DT The service date for the service, event, or confinement being billed by the provider Num 
PROV A unique system-generated number that identified the provider. It is possible for a provider 
to have multiple IDs or an ID to point to multiple physicians, particularly in the case of 
group practice. 
Num 
STD_COST An estimate of the allowed amount for the facility charges related to the confinement. 
Associated surgeon's fees are likely to be found in the medical table. 
Num 
TOS_CD Type of Service Code Char 
PROC Claim Level 1 ICD-X procedure code off of the header portion of the claim Char 
PROC1 First ICD-X Proc Code Char 
PROC2 Second ICD-X Proc Code Char 
PROC3 Third ICD-X Proc Code Char 
PROC4 Fourth ICD-X Proc Code Char 
PROC5 Fifth ICD-X Proc Code Char 
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LOS Length of Stay from start of first confinement record to end of last confinement record Num 
DIAG1 First ICD-X Diagnosis Char 
DIAG2 Second ICD-X Diagnosis Char 
DIAG3 Third ICD-X Diagnosis Char 
DIAG4 Fourth ICD-X Diagnosis Char 
DIAG5 Fifth ICD-X Diagnosis Char 
DISCH_DATE Discharge Date of Confinement (YYYYMMDD) Num 
CONF_ID Confinement Identifier. Used to identify claims records associated with an inpatient 
hospitalization. This data element is encrypted. 
Char 
ADMIT_DATE Admission Date of Confinement (YYYYMMDD) Num 
DIAG_DESC Describes the International Classification of Disease, 10th/9th Revision, Clinical 
Modification (ICD-9-CM/ICD-10-CM) code. ICD-9-CM/ICD-10-CM is designed for the 
classification of morbidity and mortality information for statistical purposes and for the 
indexing of hospital records by disease and operations, for data storage retrieval. ICD-9-
CM/ICD-10-CM is an accepted national standard for coding diagnostic and disease 
information.  
Char 
PROC_DESC Describes a specific procedure performed or service provided. A procedure code can be an 
ICD10/ICD9, CPT©, or HCPCS Level II code.  
Char 
Note: adapted from the data dictionary of Optum claims data  
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Appendix F: Acute Myocardial Infarction Codes 
Code Type Number Description 
ICD-9 41000 Acute Myocardial Infarction of Anterolateral Wall Episode of Care Unspecified 
ICD-9 41001 Acute Myocardial Infarction of Anterolateral Wall Initial Episode of Care 
ICD-9 41010 Acute Myocardial Infarction of Other Anterior Wall Episode of Care Unspecified 
ICD-9 41011 Acute myocardial infarction of other anterior wall, initial episode of care 
ICD-9 41020 Acute Myocardial Infarction of Inferolateral Wall Episode of Care Unspecified 
ICD-9 41021 Acute myocardial infarction of inferolateral wall, initial episode of care 
ICD-9 41030 Acute Myocardial Infarction of Inferoposterior Wall Episode of Care Unspecified 
ICD-9 41031 Acute myocardial infarction of inferoposterior wall, initial episode of care 
ICD-9 41040 Acute Myocardial Infarction of Other Inferior Wall Episode of Care Unspecified 
ICD-9 41041 Acute myocardial infarction of other inferior wall, initial episode of care 
ICD-9 41050 Acute Myocardial Infarction of Other Lateral Wall Episode of Care Unspecified 
ICD-9 41051 Acute myocardial infarction of other lateral wall, initial episode of care 
ICD-9 41060 True Posterior Wall Infarction Episode of Care Unspecified 
ICD-9 41061 True posterior wall infarction, initial episode of care 
ICD-9 41070 Subendocardial Infarction Episode of Care Unspecified 
ICD-9 41071 Subendocardial infarction, initial episode of care 
ICD-9 41080 Acute Myocardial Infarction of Other Specified Sites Episode of Care Unspecified 
ICD-9 41081 Acute myocardial infarction of other specified sites, initial episode of care 
ICD-9 41090 Acute Myocardial Infarction of Unspecified Site Episode of Care Unspecified 
ICD-9 41091 Acute myocardial infarction of unspecified site, initial episode of care 
ICD-10 I2101 ST Elevation (STEMI) Myocardial Infarction Involving Left Main Coronary Artery 
ICD-10 I2102 ST Elevation (STEMI) Myocardial Infarction Involving Left Anterior Descending Coronary Artery 
ICD-10 I2109 ST Elevation (STEMI) Myocardial Infarction Involving Other Coronary Artery of Anterior Wall 
ICD-10 I2111 ST Elevation (STEMI) Myocardial Infarction Involving Right Coronary Artery 
ICD-10 I2119 ST Elevation (STEMI) Myocardial Infarction Involving Other Coronary Artery of Inferior Wall 
ICD-10 I2121 ST Elevation (STEMI) Myocardial Infarction Involving Left Circumflex Coronary Artery 
ICD-10 I2129 ST Elevation (STEMI) Myocardial Infarction Involving Other Sites 
ICD-10 I213 ST Elevation (STEMI) Myocardial Infarction of Unspecified Site 
ICD-10 I214 Non-ST Elevation (NSTEMI) Myocardial Infarction 
ICD-10 I220 Subsequent ST Elevation (STEMI) Myocardial Infarction of Anterior Wall 
ICD-10 I221 Subsequent ST Elevation (STEMI) Myocardial Infarction of Inferior Wall 
ICD-10 I222 Subsequent Non-ST Elevation (NSTEMI) Myocardial Infarction 
ICD-10 I228 Subsequent ST Elevation (STEMI) Myocardial Infarction of Other Sites 
ICD-10 I229 Subsequent ST Elevation (STEMI) Myocardial Infarction of Unspecified Site 
Note: Reprinted from “Drivers of Variation in 90-Day Episode Payments After Percutaneous Coronary Intervention”[64], by 
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